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2Cyclization reactions on hexapeptides containing several Aib residues and
the turn promoting Gly and Pro residues were investigated. Eight linear
hexapeptides were synthesized and their cyclization was attempted using various
coupling reagents. The macrolactamization step proved to be difficult since only
three of these hexapeptides could be cyclized. Two of these peptides were the
linear precursors of the same cyclic hexapeptide, cyclo(Pro-Aib-Gly-Aib-Aib-
Phe) (1). Surprisingly, they gave 1 in almost the same yield. Thus, 1 was obtained
in 35% yield upon ring closure at the Phe/Pro site using DEPBT as the coupling
reagent, whereas the cyclization at the Aib/Phe site led to 1 in 28 and 34% yield
by using PyAOP and DEPC, respectively. Another cyclic hexapeptide, cyclo(Gly-
Aib-Pro-Gly-Aib-Aib) (2) was prepared in 34% yield when DEPC was used in the
cyclization step. The solid-state conformation of 1 was established by X-ray
crystallography.
31. Introduction. – Cyclic peptides usually exist in more clearly defined
conformations than their linear counterparts, and often have increased receptor
affinity and metabolic stability. Out of this arises their potential to serve as lead
structures in drug design [1]. Cyclization can also constrain a short amino acid
sequence to a turn conformation [2]. In particular, cyclic penta- and hexapeptides
have frequently been used as models for reverse turns, although the cyclization of
these small peptides is often troublesome [3]. Since peptide bonds possess
pronounced π character and preferentially adopt a trans conformation, the linear
precursor has the terminal acid and amine functions in remote positions, which is
unfavorable for cyclization. Incorporation of residues such as Gly, Pro or D-amino
acids are known to enhance cyclization yields [4].
Recently, we have focused our interest on the cyclization of model
hexapeptides containing Aib (α-aminoisobutyric acid) residues, and we were also
interested in the propensity of these cyclic peptides to form certain types of β-
turns. Since we have successfully cyclized hexapeptides containing several Aib
residues and one or two Gly residues [5], the aim of this work was to investigate
the cyclization tendencies of hexapeptides containing Aib and Pro residues. Pro is
believed to prefer turn-forming cis-peptide bonds, which should facilitate the ring
closure. In this paper we report the synthesis of cyclo(Pro-Aib-Gly-Aib-Aib-Phe)
(1) and cyclo(Gly-Aib-Pro-Gly-Aib-Aib) (2) and the attempted cyclizations of
four additional hexapeptides containing Aib and Pro residues. Furthermore, three
different linear precursors of the cyclic peptide 1 were synthesized in order to
study the influence of the amino acid sequence on the cyclization yield.
4Formulae
2. Results and Discussion. – 2.1. Preparation of Linear Peptides and
their Cyclization. The amino acid sequence of the linear precursor and the choice
of the coupling reagent are two of the most important factors that affect the result
of the cyclization reaction [6] [7]. The cyclic hexapeptide cyclo(Pro-Aib-Gly-Aib-
Aib-Phe) (1) was chosen as a model for the investigation of the significance of the
linear amino acid sequence on the success of the macrolactamization. In the
retrosynthetic analysis, three amide bonds were selected for the final ring closure
step, i.e. between Phe/Pro, Aib/Phe and Aib/Gly, respectively. These three
disconnections were likely to give different yields for the cyclization, but it was
impossible to predict with appropriate certainty which one would be optimal.
Scheme 1
The synthesis of the linear precursor for the Phe/Pro cyclization site was
carried out by stepwise elongation from the N-terminal Pro derivative (Scheme 1).
The synthesis started by coupling Fmoc-Pro-OH with the 2H-azirin-3-amine 3,
our synthon for Aib, to give the dipeptide amide 4, which was then hydrolyzed
with 3N HCl (MeCN/H2O 1:1) to give the dipeptide acid Fmoc-Pro-Aib-OH (5).
The N-terminal tripeptide Z-Gly-Aib-Aib-N(Me)Ph (6) was prepared analogously
from Z-Gly-OH by use of the ‘azirine/oxazolon method’ [8]. After removal of the
Z group from 6, PyBOP-mediated2) coupling with 5 gave pentapeptide amide 7 in
                                                 
2) For abbreviations see Exper. Part., Section 1.
569% yield. The latter was hydrolyzed to yield the peptide acid 8, which was then
coupled with H-Phe-OtBu to give the linear precursor Fmoc-Pro-Aib-Gly-Aib-
Aib-Phe-OtBu (9) in high yield. The coupling reaction was again accomplished
by use of PyBOP. Finally, after removal of the Fmoc group at the N-terminus of 9
by treatment with Et2NH and then deprotection of the t-butyl ester group at the C-
terminus with TFA, the free linear precursor as its TFA salt was subjected to
macrolactamization.
The cyclic hexapeptide 1 was initially obtained in low yield (20%) by ring
closure with TBTU/HOBt/DIEA2), however, due to the long reaction time of 6 d,
significant epimerization of the C-terminal Phe residue occurred, and afforded 1
as an inseparable mixture of two diastereoisomers. For this reason, the DEPBT2)
coupling reagent was chosen to be used in the cyclization reaction. This reagent
has proven to be very efficient in the synthesis of cyclic peptides [9] [10] with a
remarkable resistance to racemization [11]. The cyclization was carried out with
three equivalents of DEPBT in THF and high dilution (1.5 mM) and in the
presence of DIEA during 3 d. This procedure afforded cyclo(Pro-Aib-Gly-Aib-
Aib-Phe) (1) in 35% yield. No side-reactions, such as dimerization of the linear
precursor or epimerization of the C-terminal Phe residue were observed, which
allowed the desired cyclic peptide 1 to be purified easily.
The cyclization at the Aib/Phe site should be advantageous, because
epimerization is not possible when Aib is the C-terminal residue, and the steric
hindrance should be reduced compared with that of the Phe/Pro cyclization site.
Therefore, the linear precursor for this cyclization was prepared as shown in
Scheme 2. The dipeptide amide Fmoc-Pro-Aib-N(Me)Ph (4 ) was first N -
6deprotected (Et2NH in CH2Cl2) and then coupled with Z-Phe-OH using PyAOP2),
which lead to the tripeptide Z-Phe-Pro-Aib-N(Me)Ph (10) in high yield. The
hydrolysis of 10 with 3N HCl (MeCN/H2O 1:1) provided tripeptide acid 11. After
deprotection of the N-terminus of Z-Gly-Aib-Aib-OtBu (12), the reaction with 11
using HATU/HOAt as activating agents afforded hexapeptide Z-Phe-Pro-Aib-
Gly-Aib-Aib-OtBu (13) in good yield. After the removal of the Z group of 13 and
subsequent cleavage of the tert-butyl group by TFA, the linear precursor was
cyclized using different coupling reagents. The best result among the reagents
explored was achieved when DEPC ((EtO)2P(O)CN) [12] was used. The cyclic
hexapeptide 1 was obtained in 34% yield when a diluted solution (1.0 mM) of the
deprotected hexapeptide in DMF was exposed to DEPC and DIEA for 6 d at room
temperature. It should be noted that the yield of the crude cyclic product was
higher when PyAOP/HOAt was used as the cyclization reagent, and the reaction
was faster (24 h), but the purification was difficult, which resulted in a slightly
lower yield (28%) of pure 1. An additional fraction of 1, contaminated with some
Et(i-Pr)2NH+PF6-, was obtained but could not be purified. We were unable to
completely remove this byproduct by washing with aqueous citric acid and
NaHCO3 nor after two successive chromatographic purifications (AcOEt/MeOH
10:1, followed by CH2Cl2/MeOH 15:1) or crystallization. The only singlecrystals,
suitable for X-ray crystallographic analysis, that could be grown from this mixture
were co-crystals of Et(i-Pr)2NH+PF6- and 1. The formation of 1 was also attempted
using the DEPBT coupling reagent, but surprisingly the linear precursor remained
unaltered after a period of 3 d.
7Scheme 2
The linear precursor for the cyclization at the Aib/Gly site was prepared as
outlined in Scheme 4. After removal of the Z group in Z-Phe-Pro-Aib-N(Me)Ph
(10), condensation with Z-Gly-Aib-Aib-OH using PyAOP/HOAt provided the
linear hexapeptide 14 in 90% yield. The deprotection of 14 afforded the free
linear precursor, which was subjected to macrolactamization with four different
coupling reagents, i.e., DEPC, DEPBT, PyAOP/HOAt, and HATU/HOAt.
Unfortunately, all four attempts failed and only decomposition of the coupling
reagents was observed. This result was very surprising since we have previously
successfully cyclized several Aib-containing hexapeptides at an Aib/Gly site in
good yields (45-57%) [5] [13]. We assume that the Pro residue at position 5 of the
sequence makes the peptide more rigid, thereby completely preventing
cyclization.
Scheme 3
The incorporation of Gly or Pro residues as turn-inducing elements is
generally considered as a prerequisite for the ring closure of short peptides [14].
Since the cyclic peptide 1 contains both of these residues, the cyclization was
expected to proceed in high yield. The observed moderate yields (28-35%) were
presumably caused by the presence of three conformationally constrained Aib
units in the sequence, in addition to one conformationally restricted Pro residue,
thus evoking highly constrained linear precursors. Based on these precedents, we
8decided to prepare a similar cyclohexapeptide, i.e. cyclo(Gly-Aib-Pro-Gly-Aib-
Aib) (2), which contains an additional Gly instead of Phe. Furthermore, one Gly
residue is placed adjacent to the Pro unit, which should hopefully decrease the
conformational constraint and enhance the cyclization yield. The synthesis of the
linear precursor of 2 and its cyclization are shown in Scheme 4. After removal of
the Z group of tripeptide 6, condensation with Fmoc-Pro-OH using PyAOP
yielded the linear tetrapeptide Fmoc-Pro-Gly-Aib-Aib-N(Me)Ph (15). Treatment
of 15 with Et2NH gave the N-deprotected tetrapeptide, which on subsequent
coupling with Z-Gly-Aib-OH using PyAOP led to the linear hexapeptide Z-Gly-
Aib-Pro-Gly-Aib-Aib-N(Me)Ph (16). The latter was hydrolyzed to give the
peptide acid 17, the Z group was removed hydrogenolytically, and the free linear
precursor subjected to cyclization in DMF (1.5 mM) by using DEPC (4 equiv.) as
the coupling reagent in the presence of DIEA. The cyclopeptide 2 was obtained as
a white precipitate, which was almost insoluble in organic solvents and H2O.
Since chromatographic purification was not possible, 2 was collected by filtration,
washed with H2O, MeOH and CH2Cl2 to remove excess coupling reagent and
some byproducts and was recrystallized from hot H2O/MeOH/EtOH solution. In
this way, pure cyclohexapeptide 2 was obtained in 34% yield3).
                                                 
3) The cyclization was not repeated using other coupling reagents such as PyAOP, DEPBT or
HATU because, in contrast to DEPC, they are solid materials and it would not be possible to
remove them from the cyclic product merely by filtration and washing. In addition, they usually
generate much more of the byproducts during cyclization or work up, with some byproducts
arising from the decomposition of excess coupling reagent.
9Due to the low solubility of 2, the NMR spectra had to be performed in
DMSO containing small amounts of TFA. Surprisingly, although the linear
precursor of 2 possesses the turn-inducing Pro-Gly segment in the middle of the
sequence and two residues (Aib and Gly) at the C- and N-terminus, which can
both be considered as pseudo-D- and L-amino acids, the cyclization was no more
effective than in the case of 1.
Scheme 4
Recently, we have synthesized a cyclic hexapeptide in which Aib residues
alternate with proteinogenic amino acids, i.e., cyclo(Gly-Aib-Leu-Aib-Phe-Aib)
[15]. The conformation of this cyclic peptide in solution was well defined and it
was shown that it is very similar to the conformation adopted in the solid state.
Furthermore, the cyclization yield was surprisingly high (53%), although the Aib
unit situated between the two large Leu and Phe residues was forced to assume a
fully extended conformation, as shown by X-ray crystallography and MD
simulations. It is unfavorable and highly uncommon for an Aib residue to adopt
extended conformations. Thus, we decided to replace Leu by Pro in order to see
how this modification would affect the cyclization yield and the conformational
preference of the Aib residues. The synthesis of the linear precursor is outlined in
Scheme 5. After Fmoc deprotection of dipeptide amide 4, the coupling with Z-
Gly-Aib-OH using the PyAOP reagent gave tetrapeptide Z-Gly-Aib-Pro-Aib-
N(Me)Ph (18) in high yield. The latter was hydrolyzed (3N HCl (MeCN/H2O
1:1)) to give peptide acid 19. The Z group of Z-Phe-Aib-OtBu (20) was removed,
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and the subsequent coupling with 19 by using of PyAOP provided hexapeptide Z-
Gly-Aib-Pro-Aib-Phe-Aib-OtBu (21) in moderate yield. After the removal of the
protecting groups, the linear precursor was subjected to cyclization, but both
DEPBT and PyBOP, failed to give cyclo(Gly-Aib-Pro-Aib-Phe-Aib) (22).
Unfortunately, we were unable to grow crystals of the linear hexapeptide suitable
for an X-ray crystal structure analysis in order to evaluate the conformational
constraints of the linear precursor.
Scheme 5
Scheme 6
Next, we prepared a similar hexapeptide, with Pro at the N-terminus and
the Gly residue in the middle of the sequence, with the aim of facilitating the
cyclization (Scheme 6). Starting with the dipeptide amide 23 and Fmoc-Pro-Aib-
OH (5), and using HATU/HOAt as the coupling reagent, the tetrapeptide amide
Fmoc-Pro-Aib-Gly-Aib-N(Me)Ph (24) was obtained and hydrolyzed to give 25.
Coupling of H-Phe-Aib-N(Me)Ph, generated by hydrogenolysis from Z-Phe-Aib-
N(Me)Ph (26) [16] with 25 by using TBTU/HOBt afforded Fmoc-Pro-Aib-Gly-
Aib-Phe-Aib-N(Me)Ph (27). After deprotection, the linear precursor was
subjected to cyclization. Unfortunately, both PyAOP and DEPBT did not lead to
cyclo(Pro-Aib-Gly-Aib-Phe-Aib) (28). Since the linear precursor of 28, as in the
case of 22, remained unaltered upon exposure to the coupling reagents and the
11
base over a period of several days, we suppose that these hexapeptide sequences
form rigid extended conformations which prevent cyclization.
Scheme 7
The cyclic Pro- and Aib-containing pentapeptide cyclo(Gly-Aib-Pro-Aib-
Aib) has previously been synthesized in excellent yield (89%) using DEPC/DIEA
in DMF in an overnight reaction [16]. The linear precursor of this cyclic
pentapeptide apparently possess a cyclization-prone conformation in DMF
solution. Although it is known that minor changes in peptide sequence can
significantly affect cyclization, we hoped that by incorporation of an additional
Aib residue into the above sequence, the conformational preference of the linear
precursor would not be altered too much and would, therefore, lead to the cyclic
hexapeptide in good yield. The synthesis of the linear precursor containing Gly,
Pro and four Aib residues is outlined in Scheme 7. PyBOP-mediated condensation
of Fmoc-Pro-Aib-OH (5) with H-Aib-OtBu gave tripeptide Fmoc-Pro-Aib-Aib-
OtBu (29) in good yield. Removal of the Fmoc group of 29 followed by a second
PyBOP-mediated coupling with Z-Gly-Aib-Aib-OH provided Z-Gly-Aib-Aib-
Pro-Aib-Aib-OtBu (30) in moderate yield. Finally, the protecting groups were
removed and the linear precursor was subjected to cyclization. However, all
attempts using either DEPBT/DIEA/DMF or DEPC/DIEA/DMF and prolonged
reaction time (3-10 d) failed to give cyclopeptide 31.
Since the cyclization of hexapeptides containing one Pro and several Aib
residues remained difficult, the incorporation of two Pro units seemed reasonable.
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As cyclo(Pro-Aib-Gly-Aib-Aib-Phe) 1 has been synthesized successfully,
although in moderate cyclization yields (28-35%), an analogous peptide with Gly
replaced by an additional Pro residue was prepared (Scheme 7). Thus, the reaction
of 5 with 3 in THF (6 d) afforded tripeptide amide Fmoc-Pro-Aib-Aib-N(Me)Ph
(32) in good yield. After removal of the Fmoc group of 32, the HATU/HOAt-
mediated coupling with Z-Phe-Pro-Aib-OH (11) gave hexapeptide Z-Phe-Pro-
Aib-Pro-Aib-Aib-N(Me)Ph (33). The protecting groups were removed and the
linear precursor subjected to cyclization, but no cyclic peptide 34 was formed
after treatment with either PyAOP/HOAt or EDCI/HOAt for 3 d.
In summary, the cyclization of various hexapeptides containing Pro and
three or four Aib residues has been investigated. In contrast to the general rule
that Pro residues in linear peptides promote the formation of cyclization-prone
conformations, our experimental data showed that the introduction of Pro into the
peptide sequence containing Aib residues drastically hinders the formation of
cyclic hexapeptides regardless of the position of Pro in the linear sequence. A
total of 18 cyclization reactions were carried out in order to study the propensity
of these hexapeptides to form cyclomonomers, but only three reactions were
successful and resulted in moderate yields of cyclopeptides 1 or 2. During
cyclizations that fail to produce cyclomonomers, the formation of cyclic dimers or
oligomers is commonly observed, but in the present study, the linear precursors
either formed cyclomonomers in moderate yields or remained unaltered. One
possible explanation for this observation might be the preference of rigid extended
conformations when conformationally restricted proline along with
13
conformationally constrained Aib units are incorporated in short peptide
sequences (cf. also [17]).
2.3. Solid State Conformation of Cyclo(Phe-Pro-Aib-Gly-Aib-Aib-Phe) 1.
Cyclic hexapeptides generally adopt conformations consisting of two β-turns,
often referred to as the turn-extended-turn conformation [18]. A proline residue,
in which the N-C(α ) torsion angle φ  is restricted to –60° (±20°) induces
characteristic turn motifs within the cyclic peptides. As a consequence of this
reduced conformational space, Pro strongly prefers the (i + 1)-position of most β-
turns [19]. In Pro-Xaa sequences, the preference for a certain type of β-turn
conformation depends on the structure of the Xaa residue, such as L/D
configuration and side chain nature, as well as on the environment (solid or
solution state, solvent polarity) [20].
We have carried out an X-ray crystallographic investigation of the
molecular structure of 1 in order to study the effect that the Pro and Aib residues
might have on the conformation of small cyclic peptides. Crystals were grown
from the fraction containing 1 and some Et(i-Pr)2NH+PF6- by slow evaporation of
a solution in AcOEt/EtOH/hexane. The cyclic peptide 1 co-crystallized with Et(i-
Pr)2NH+PF6- and H2O in a ratio 1:1:1. The ORTEP plot [21] of the molecular
structure with the atom numbering scheme is presented in Figure 1. The relevant
torsion angles for 1 are summarized in Table 1, and the H-bond parameters are
shown in Table 2.
Fig. 1
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The overall conformation of cyclo(Pro1-Aib2-Gly3-Aib4-Aib5-Phe6) (1 )
consists of two β-turns stabilized by a pair of intramolecular H-bonds involving
the CO and NH groups of the Gly and Phe residues. The torsion angles φ and ψ of
the Aib4 and Aib5 residues in the Gly3-Aib4-Aib5-Phe6 segment show values close
to those for a type I’ β-turn (Table 1). The sequence Phe6-Pro1-Aib2-Gly3 adopts a
type III β-turn conformation with Pro1 at the (i + 1)-position of the turn, as
expected for this residue. All three Aib residues show torsion angles which are in
good agreement with the expected values in the helical region of the
conformational space. In addition, all the amide bonds have the trans
conformation. Since structural information about the conformational preferences
of Aib- and Pro-containing cyclic hexapeptides is scarce, our results cannot be
compared with other data. To the best of our knowledge, the solution structure of
cyclo(Pro-Leu-Aib)2 is, so far, the only example of an Aib- and Pro-containing
cyclic hexapeptide with a known conformation [22]. The NMR spectra and
temperature coefficients of this cyclic peptide indicate an asymmetric
conformation which contains both cis and trans Aib-Pro bonds. Therefore, the
overall conformation consists of two β-turns of type II’ and VI with Pro residues
occupying the (i + 2)-positions of the turns.
Table 1
Table 2
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Experimental Part
1. General. Solvents were purified by standard procedures. The used Aib-
synthon was 2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine (3) [23]. Thin-layer
chromatography (TLC): Merck TLC aluminium sheets, silica gel 60 F254. Column
chromatography (CC): Uetikon-Chemie ’Chromatographiegel’ C-560. M.p: Büchi
5 1 0  apparatus; uncorrected. IR Spectra: Perkin-Elmer-1600 FT-IR
spectrophotometer; in KBr; absorptions in cm-1. 1H- (300 MHz) and 13C-NMR
(75.5 MHz) Spectra: Bruker ARX-300 instrument; in (D6)DMSO at 300 K unless
otherwise stated; δ in ppm, coupling constants J in Hz. MS: Finnigan SSQ-700 or
MAT-90 instrument for CI; Finnigan TSQ-700 triple quadrupole spectrometer for
ESI; m/z (rel.%). Abbreviations: DEPBT: 3-(diethoxyphosphoryloxy)-1,2,3-
benzotriazin-4(3H)-one, DEPC: diethylphosphorocyanidate, DIEA: N-ethyl-N,N-
diisopropylamine, EDCI: N -ethyl-N’-(3-dimethylaminopropyl)carbodiimide,
Fmoc: (fluoren-9-yl)methoxycarbonyl, HATU: O-(7-azabenzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluorophosphate, HOAt: 1-hydroxy-7-
azabenzotriazole, HOBt: 1-hydroxybenzotriazole, PyAOP: (7-azabenzotriazol-1-
yloxy)tris(pyrrolidino)phosphonium hexafluorophosphate, PyBOP: (1H-
benzotriazol-1-yloxy)tris(pyrrolidino)phosphonium hexafluorophosphate, TBTU:
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate, Z:
benzyloxycarbonyl.
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General Procedure 1 (GP 1). To a soln. of an N-protected amino acid or
peptide acid in abs. THF or MeCN was added the 2H-azirin-3-amine 3 (1.1
equiv.) in abs. THF, and the mixture was stirred at r.t. under N2. After completion
of the reaction (TLC), the solvent was evaporated i.v. and the residue purified by
CC (SiO2).
General Procedure 2 (GP 2). The peptide amide was dissolved in 3N
HCl/MeCN 1:1 (v/v; 10 ml/mmol), and the soln. was stirred at r.t. overnight. The
mixture was extracted with CH2Cl2 or AcOEt, dried (Na2SO4), and evaporated.
The crude product was purified by CC or crystallization and dried u.h.v.
General Procedure 3 (GP 3). To a soln. of a Z-protected peptide in MeOH
was added Pd/C (10%) and the mixture was hydrogenated overnight under
atmospheric pressure using an H2-filled balloon. The catalyst was removed by
filtration through a pad of celite and the solvent evaporated. The residue was
purified by chromatography on a short plug of SiO2 using CH2Cl2/MeOH/NH3(l)
12:1:0.1 as eluant.
General Procedure 4 (GP 4). To a soln. of an N-protected peptid acid in
the given solvent were added the amino component (1.1 equiv.), coupling reagent
(1.0-1.1 equiv.), additive (HOAt or HOBt, 1.0-1.1 equiv.) if indicated, and DIEA
(2 equiv. without and 3 equiv. with hydrochloride salts present). The mixture was
stirred at r.t. under N2 until the starting material was consumed (TLC). The
solvent was then evaporated, the residue was dissolved in AcOEt and washed with
5% aq. KHSO4 soln., 5% aq. NaHCO3 soln. and brine. The org. layer was dried
(MgSO4), concentrated, purified by CC and dried i.v.
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General Procedure 5 (DEPBT-mediated Cyclization) (GP 5). Free linear
hexapeptide was dissolved in abs. DMF (1.5 mM) under stirring. DEPBT (3-5
equiv.) and DIEA (1% v/v) were then added at r.t. and the solution was stirred for
an additional 3 d. The solvent was evaporated under reduced pressure, and the
crude cyclopeptide was purified by CC and prep. TLC.
General Procedure 6 (DEPC-mediated Cyclization) (GP 6). Free linear
hexapeptide was dissolved in abs. DMF (1.0-1.5 mM) and the soln. was cooled to
0° in an ice bath. A soln. of 3-5 equiv. of DEPC in abs. DMF (1 ml) was added
under stirring. Then, DIEA (1% v/v) was added slowly over a period of 15 min.
The soln. was warmed to r.t. and stirred for an additional 6 d. The solvent was
then evaporated under reduced pressure, the residue was taken up in AcOEt and
washed with 5% aq. KHSO4 soln., 5% aq. NaHCO3 soln. and brine. The org.
phase was dried (MgSO4) and concentrated to give the crude cyclohexapeptide,
which was purified by CC.
General Procedure 7 (PyAOP-mediated Cyclization) (GP 7). Free linear
hexapeptide was dissolved in abs. DMF (0.5-1.0 mM) under stirring. PyAOP (3 or
5 equiv.), HOAt (3 or 5 equiv., 0.5 M soln. in DMF) and DIEA were then added at
r.t. The soln. was stirred at r.t. for an additional 3 d. The solvent was then
removed under reduced pressure, the residue dissolved in AcOEt and washed with
10% citric acid soln., 5% NaHCO3 soln. and H2O. The org. layer was dried
(Na2SO4), filtered and concentrated to afford a yellow oil which was purified by
CC.
2. Preparation of Fmoc-Pro-Aib-Gly-Aib-Aib-Phe-OtBu (9).
18
2.1. Fmoc-Pro-Aib-N(Me)Ph (4). According to the GP 1 with Fmoc-Pro-
OH (4.0 g, 11.85 mmol) in 50 ml abs. THF, 3 (2.272 g, 13.04 mmol) in 5 ml abs.
THF, stirred for 60 h. CC (AcOEt/hexane 2:1) yielded 5.39 g (89%) of 4 as a
white foam. IR: 3305s, 3063m, 2980m, 2948m, 2880m, 1703s, 1635s, 1594s,
1535m, 1493s, 1451s, 1417s, 1359s, 1289m, 1243m, 1192m, 1118s, 1090s, 988m,
760s, 741s, 705m.1H-NMR: 8.09 (s, NH); 7.91-7.18 (m, 13 arom. H); 4.34-4.11
(m, CHCH2O of Fmoc, CH(2) of Pro); 3.48-3.35 (m, CH2(5) of Pro); 3.24 (s,
MeN); 2.19-1.82 (m, CH2(3) and CH2(4) of Pro); 1.37, 1.35 (2s, 2 Me of Aib).
13C-NMR: 172.1, 170.6 (2s, 2 CO); 154.0 (s, CO (urethane)); 145.6, 143.8, 143.6,
140.6 (4s, 5 arom. C); 128.5, 127.5, 127.3, 127.0, 126.2, 125.0, 120.0 (7d, 13
arom. CH); 66.4 (t, CHCH2O of Fmoc); 59.4 (d, C(2) of Pro); 56.1 (s, C(2) of
Aib); 46.5 (d, CHCH2O of Fmoc); 46.3 (t, C(5) of Pro); 39.6 (q, MeN); 29.7 (t,
C(3) of Pro); 26.0, 25.7 (2q, 2 Me of Aib); 23.7 (t, C(4) of Pro). ESI-MS
(MeOH+NaI): 534 (100, [M+Na]+). Anal. calc. for C31H33N3O4 (511.62): C 72.78,
H 6.50, N 8.21; found: C 72.71, H 6.59, N 8.17.
2.2. Fmoc-Pro-Aib-OH (5). According to the GP 2, 4 (5.3 g, 10.35 mmol)
in 3N HCl (MeCN/H2O 1:1, 100 ml), stirred overnight. The product was extracted
with AcOEt and purified by CC (AcOEt/MeOH 20:1) to give 3.22 g (74%) of
pure 5. White powder. M.p. 170.0-171.5°. IR: 3364m, 2987m, 2946m, 2895m,
2536w, 1706s, 1628s, 1528s, 1463s, 1451s, 1408s, 1356m, 1345s, 1328s, 1270m,
1252m, 1204s, 1175s, 1128m, 988w, 925w, 862w, 760s, 741s. 1H-NMR: 8.21
(br.s, NH); 8.00-7.30 (m, 8 arom. H); 4.40-4.00 (m, CHCH2O of Fmoc, CH(2) of
Pro); 3.44-3.32 (m, CH2(5) of Pro); 2.24-1.82 (m, CH2(3) and CH2(4) of Pro);
1.36, 1.33 (2s, 2 Me of Aib). 13C-NMR: 175.3, 171.2 (2s, 2 CO); 153.8 (s, CO
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(urethane)); 144.0, 143.7, 143.4, 140.6 (4s, 4 arom. C); 127.5, 127.0, 125.5, 125.2,
125.0, 120.0 (6d, 8 arom. CH); 66.7 (t, CHCH2O of Fmoc); 59.2 (d, C(2) of Pro);
54.8 (s, C(2) of Aib); 47.0 (t, C(5) of Pro); 46.5 (d, CHCH2O of Fmoc); 31.0 (t,
C(3) of Pro); 25.1, 24.4 (2q, 2 Me of Aib); 22.7 (t, C(4) of Pro). ESI-MS (MeOH):
445 (48, [M+Na]+), 423 (100, [M+H]+). Anal. calc. for C24H26N2O5 (422.48): C
68.23, H 6.20, N 6.63; found: C 68.10, H 6.28, N 6.42.
2.3. Fmoc-Pro-Aib-Gly-Aib-Aib-N(Me)Ph (7). Z-Gly-Aib-Aib-N(Me)Ph (6
[5], 0.54 g, 1.15 mmol) was N-deprotected following GP 3 (H2, 60 mg Pd/C, 6 ml
MeOH, overnight). Purification by CC (CH2Cl2/MeOH 15:1) yielded 0.385 g
(1.15 mmol, quant. yield) of H-Gly-Aib-Aib-N(Me)Ph as a white foam, which
was used directly in the next step.
The coupling of Fmoc-Pro-Aib-OH (5, 0.442 g, 1.05 mmol) and the above-
prepared H-Gly-Aib-Aib-N(Me)Ph (0.385 g, 1.15 mmol) was carried out using
PyBOP (0.544 g, 1.05 mmol) and DIEA (0.27 g, 2.1 mmol) in 10 ml abs.
CH2Cl2/MeCN (4:1) according to the GP 4. Purification by CC (AcOEt/MeOH
13:1, CH2Cl2/MeOH 15:1) yielded 0.536 g (69%) of 7. White powder. M.p. 136-
138°. IR: 3323m, 3064w, 2984m, 2940m, 1673s, 1594m, 1534s, 1494m, 1452s,
1425m, 1391m, 1361m, 1336m, 1281m, 1244m, 1195m, 1168m, 1125m, 1091m,
1017w, 991w, 760m, 741m, 708m . 1H-NMR: 8.77, 8.04, 7.90, 7.88 (4s, 4 NH);
7.64-7.15 (m, 13 arom. H); 4.37-4.12 (m, CHCH2O of Fmoc, CH(2) of Pro); 3.52-
3.41 (m, CH2 of Gly, CH2(5) of Pro); 3.22 (s, MeN); 2.15-1.85 (m, CH2(3) and
CH2(4) of Pro); 1.39, 1.36, 1.28, 1.21 (4s, 6 Me of 3 Aib). 13C-NMR (CD3OD):
178.1, 176.2, 175.5, 175.2, 171.6 (5s, 5 CO); 156.8 (s, CO(urethane)); 147.0,
145.0, 144.9, 142.5 (4s,  5 arom. C); 130.2, 128.9, 128.1, 126.2, 125.9, 121.0 (6d,
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13 arom. CH); 69.0 (t, CHCH2O of Fmoc); 61.5 (d, C(2) of Pro); 58.4, 58.2, 57.6
(3s, 3 C(2) of 3 Aib); 48.24 (t, C(5) of Pro); 48.20 (d, CHCH2O of Fmoc); 45.4 (t,
C(2) of Gly); 41.0 (q, MeN); 31.0 (t, C(3) of Pro); 25.6 (t, C(4) of Pro); 27.1,
26.5, 26.4, 26.1, 24.4, 24.0 (6q, 6 Me of 3 Aib). ESI-MS (MeOH/CH2Cl2): 784
(32, [M+K]+), 632 (100, [M-N(Me)Ph]+). Anal. calc. for C41H50N6O7•1/2H2O
(747.89): C 65.84, H 6.87, N 11.24; found: C 65.87, H 6.80, N 11.25.
2.4. Fmoc-Pro-Aib-Gly-Aib-Aib-OH (8). According to the GP 2 with 7
(0.478 g, 0.65 mmol) in 6 ml 3N HCl (MeCN/H2O 1:1), stirred overnight. The
solvent was evaporated under reduced pressure and 5 ml of H2O were added. The
precipitated product was filtered, washed with H2O and Et2O and dried u.h.v. to
give 0.38 g (91%) of pure 8. White powder. M.p. 185.5-187.5°. IR: 3325m,
2983m, 2938m, 1662s, 1603m, 1525s, 1452s, 1362m, 1338m, 1289m, 1210m,
1133m, 1019w, 989w, 942w, 868w, 759m, 741m. 1H-NMR (CD3OD): 7.80-7.28
(m, 8 arom. H); 4.43-4.21 (m, CHCH2O of Fmoc, CH(2) of Pro); 3.76-3.50 (m,
CH2 of Gly, CH2(5) of Pro); 2.22-1.88 (m, CH2(3) and CH2(4) of Pro); 1.48, 1.43,
1.31, 1.19 (4s, 6 Me of 3 Aib). 13C-NMR (CD3OD): 181.3, 179.9, 176.1, 174.6,
169.7 (5s, 6 CO); 156.4 (s, CO(urethane)); 144.8, 143.1, 142.4 (3s, 4 arom. C);
128.9, 128.0, 127.7, 126.0, 125.7, 121.0, 120.9 (7d, 8 arom. CH); 70.2 (t,
CHCH2O of Fmoc); 60.7 (d, C(2) of Pro); 58.6, 58.3, 57.1 (3s, 3 C(2) of 3 Aib);
48.6 (t, C(5) of Pro); 47.4 (d, CHCH2O of Fmoc); 44.7 (t, C(2) of Gly); 31.3 (t,
C(3) of Pro); 25.7 (t, C(4) of Pro); 25.0, 24.3, 24.1, 22.9 (4q, 6 Me of 3 Aib). ESI-
MS (MeOH+NaI): 672 (100, [M+Na]+).
2.5. Fmoc-Pro-Aib-Gly-Aib-Aib-Phe-OtBu (9). According to the GP 4,
coupling of 8 (0.338 g, 0.52 mmol) with HCl•H-Phe-OtBu (0.147 g, 0.57 mmol),
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using PyBOP (0.27 g, 0.52 mmol) and DIEA (0.2 g, 1.56 mmol) in 10 ml abs.
CH2Cl2/MeCN (3:2). Reaction time: 20 h. The crude product was purified by CC
(CH2Cl2/MeOH 20:1) to yield 0.358 g (81%) of 9. White powder. M.p. 166.5-
167.5°. IR: 3323m, 2981m, 2936m, 1671s, 1535s, 1453s, 1425m, 1363m, 1336m,
1283m, 1247m, 1160s, 1128m , 990w, 847w , 759m , 741m , 701m . 1H-NMR
(CD3OD): 7.79-7.15 (m, 13 arom. H); 4.44-4.17 (m, CHCH2O of Fmoc, CH(2) of
Phe, CH(2) of Pro); 3.87-3.50 (m, CH2 of Gly, CH2(5) of Pro); 3.07-3.02 (m, CH2
of Phe); 2.25-1.85 (m, CH2(3) and CH2(4) of Pro); 1.44, 1.42, 1.41, 1.35, 1.30,
1.15 (6s, 6 Me of 3 Aib, Me3C). 13C-NMR (CD3OD): 177.9, 176.9, 175.8, 175.2,
172.2, 172.1 (6s, 6 CO); 156.8 (s, CO(urethane)); 145.0, 144.9, 142.6, 138.5 (4s, 5
arom. C); 130.4, 129.2, 128.9, 128.1, 127.5, 126.1, 125.9, 121.0 (8d, 13 arom.
CH); 82.4 (s, Me3C); 69.0 (t, CHCH2O of Fmoc); 61.5, 56.5 (2d, C(2) of Pro, C(2)
of Phe); 48.3 (t, C(5) of Pro); 48.2 (d, CHCH2O of Fmoc); 45.3, 38.4 (2t, C(2) of
Gly, C(3) of Phe); 31.0 (t, C(3) of Pro); 28.1 (q, Me3C); 26.9, 26.8, 26.7 (3q, 6 Me
of 3 Aib); 25.6 (t, C(4) of Pro). ESI-MS (MeOH+NaI): 876 (100, [M+Na]+). Anal.
calc. for C47H60N6O9•1/3H2O (859.03): C 65.71, H 7.12, N 9.78; found: C 65.70,
H 7.26, N 9.72.
3. Preparation of Z-Phe-Pro-Aib-Gly-Aib-Aib-OtBu (13).
3.1. Z-Phe-Pro-Aib-N(Me)Ph (10). A soln. of Fmoc-Pro-Aib-N(Me)Ph (4,
2.479 g, 4.84 mmol) in 20 ml CH2Cl2/Et2NH (1:1) was stirred for 3 h at r.t. The
solvents were removed under reduced pressure and the crude N-deprotected
peptide was purified by CC (CH2Cl2/MeOH 12:1) to give 1.21 g (86%) of H-Pro-
Aib-N(Me)Ph, which was used directly in the next step.
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The above-prepared dipeptide (1.21 g, 4.18 mmol) was coupled with Z-Phe-OH
(1.138 g, 3.8 mmol) according to the GP 4, by using PyAOP (2.19 g, 4.2 mmol)
and DIEA (1.36 g, 10.5 mmol) in 15 ml abs. CH2Cl2. Reaction time: 24 h. The
crude product was purified by CC (AcOEt/MeOH 15:1, CH2Cl2/MeOH 35:1) to
yield 1.94 g (89%) of pure 10 as a white foam. IR: 3416m, 3304s, 3061m, 3031m,
2981m, 2946m, 1715s, 1683s, 1643s, 1593m , 1531s, 1494s, 1453s, 1389m,
1361m, 1245s, 1211m, 1116m, 1089m, 1044m, 1027m, 1002w, 845w , 774m,
748m, 701s. 1H-NMR: 8.06 (s, NH of Aib); 7.64 (d, J = 8.2, NH of Phe); 7.37-
7.14 (m, 15 arom. H); 4.96 (s, PhCH2O); 4.47-4.31 (m, CH(2) of Phe, CH(2) of
Pro); 3.69-3.50 (m, CH2(5) of Pro); 3.27 (s, MeN); 3.04-2.73 (m, CH2 of Phe);
2.05-1.77 (m, CH2(3) and CH2(4) of Pro); 1.38, 1.37 (2s, 2 Me of Aib). 13C-NMR:
172.1, 170.2, 170.1 (3s, 3 CO); 155.8 (s, CO(urethane)); 145.7, 137.8, 136.9 (3s, 3
arom. C); 129.1, 128.6, 128.1, 128.0, 127.6, 127.4, 127.3, 126.2 (8d, 15 arom.
CH); 65.1 (t, PhCH2O); 59.1 (d, C(2) of Pro); 56.0 (s, C(2) of Aib); 54.3 (d, C(2)
of Phe); 46.6 (t, C(5) of Pro); 39.6 (q, MeN); 36.3 (t, C(3) of Phe); 28.7 (t, C(3) of
Pro); 26.1, 25.4 (2q, 2 Me of Aib); 24.3 (t, C(4) of Pro). ESI-MS (MeOH+NaI):
593 (100, [M+Na]+). Anal. calc. for C33H38N4O5•1/2H2O (579.70): C 68.37, H
6.78, N 9.66; found: C 68.50, H 6.76, N 9.58.
3.2. Z-Phe-Pro-Aib-OH (11). According to the GP 2, 10 (0.68 g, 1.19
mmol) in 12 ml 3N HCl (MeCN/H2O 1:1), stirred overnight. Purification by CC
(CH2Cl2/MeOH 15:1) yielded 0.519 g (91%) of 11 as a white foam. IR: 3416s,
3063m, 3031m, 2982m, 1714s, 1640s, 1529s, 1454s, 1341m, 1247s, 1214s, 1162s,
1081m, 1051m, 1003w, 913w, 749m, 700s. 1H-NMR: 7.94 (s, NH of Aib); 7.58 (d,
J = 8.4, NH of Phe); 7.36-7.18 (m, 10 arom. H); 4.95 (br.s, PhCH2O); 4.46-4.28
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(m, CH(2) of Pro and CH(2) of Phe); 3.67-3.23 (m, CH2(5) of Pro); 3.04-2.73 (m,
CH2(3) of Phe); 2.03-1.64 (m, CH2(3) and CH2(4) of Pro); 1.37, 1.35 (2s, 2 Me of
Aib). 13C-NMR: 175.9, 170.1, 170.0 (3s, 3 CO); 155.8 (s, CO(urethane)); 137.8,
136.9 (2s, 2 arom. C); 129.1, 128.1, 127.9, 127.5, 127.3, 126.1 (6d, 10 arom. CH);
65.1 (t, PhCH2O); 59.4 (d, C(2) of Pro); 55.0 (s, C(2) of Aib); 54.3 (d, C(2) of
Phe); 46.6 (t, C(5) of Pro); 36.3 (t, C(3) of Phe); 28.5 (t, C(3) of Pro); 24.8, 24.2
(2q, 2 Me of Aib); 24.3 (t, C(4) of Pro). CI-MS (NH3): 482 (27, [M+H]+), 464
(100, [M-OH]+). Anal. calc. for C26H31N3O6•1/2H2O (490.55): C 63.66, H 6.57, N
8.56; found: C 63.57, H 6.32, N 8.37.
3.3. Z-Phe-Pro-Aib-Gly-Aib-Aib-OtBu (13). Z-Gly-Aib-Aib-OtBu (12 [5],
0.425 g, 0.98 mmol) was N-deprotected (H2, 50 mg Pd/C, 6 ml MeOH) according
to the GP 3. 0.294 g (quant. yield) of H-Gly-Aib-Aib-OtBu were obtained and
used directly in the next step without further purification.
Coupling of the above deprotected tripeptide (0.294 g, 0.98 mmol) with 11
(0.427g, 0.89 mmol) was accomplished according to the GP 4 by using HATU
(0.342 g, 0.9 mmol), HOAt (0.9 mmol, 1.8 ml 0.5M DMF-solution) and DIEA
(0.232 g, 1.8 mmol) in 10 ml abs. CH2Cl2. Reaction time: 20 h. The crude material
was purified by CC (CH2Cl2/MeOH 15:1) to give 0.495 g (73%) of pure 13 as a
white foam. IR: 3328s, 3063w, 3031w, 2982m, 2937m, 1670s, 1529s, 1454s,
1386m, 1367m, 1310m, 1252m, 1149s, 1083w, 1044m, 919w, 850s, 751m, 699m.
1H-NMR: 8.90 (s, NH of Aib); 8.27 (t-like, NH of Gly); 7.74 (d, J = 8.5, NH of
Phe); 7.46 (s, NH of Aib); 7.35-7.21 (m, 10 arom. H); 7.13 (s, NH of Aib); 4.93-
4.92 (m, PhCH2O); 4.45-4.37 (m, CH(2) of Pro and CH(2) of Phe); 3.81-3.50 (m,
CH2(5) of Pro and CH2 of Gly); 2.89-2.66 (m, CH2 of Phe); 2.18-1.80 (m, CH2(3)
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and CH2(4) of Pro); 1.43, 1.37, 1.32, 1.30, 1.29, 1.26 (6s, 6 Me of 3 Aib, Me3C).
13C-NMR: 175.7, 173.0, 172.8, 171.0, 168.5 (5s, 6 CO); 155.9 (s, CO(urethane));
137.5, 136.8 (2s, 2 arom. C); 129.1, 128.2, 128.1, 127.7, 127.5, 126.4 (6d, 10
arom. CH); 78.9 (s, Me3C); 65.3 (t, PhCH2O); 60.0 (d, C(2) of Pro); 56.0, 55.7,
55.2 (3s, 3 C(2) of 3 Aib); 54.5 (d, C(2) of Phe); 47.0 (t, C(5) of Pro); 44.4 (t,
C(2) of Gly); 36.4 (t, C(3) of Phe); 28.3 (t, C(3) of Pro); 27.4 (q, Me3C); 25.0 (t,
C(4) of Pro); 26.6, 25.9, 25.1, 23.8, 23.6, 23.4 (6q, 6 Me of 3 Aib). ESI-MS
(MeOH+NaI): 788 (100, [M+Na]+).
4. Synthesis of Cyclo(Pro-Aib-Gly-Aib-Aib-Phe) (1).
4.1. Cyclo(Pro-Aib-Gly-Aib-Aib-Phe) (1) from 9. To a soln. of 9 (0.318 g,
0.37 mmol) in 4 ml MeCN was added 1.2 ml Et2NH at r.t. and the mixture was
stirred for 3 h. The solvents were then removed under reduced pressure and the
residue purified by CC (CH2Cl2/MeOH 15:1) to give 0.227 g (96%) H-Pro-Aib-
Gly-Aib-Aib-Phe-OtBu as a white foam. This N-deprotected hexapeptide (0.227
g, 0.35 mmol) was dissolved in 10 ml CH2Cl2 and TFA (10 ml) was then added.
The mixture was stirred for 5 h at r.t. Excess TFA was evaporated under reduced
pressure and the remaining TFA was removed by co-evaporation with Et2O (3x 5
ml). The residue was triturated with Et2O, the soln. decanted, and the operation
was repeated twice to afford, after drying i.v., 0.257 g (0.35 mmol, quant. yield)
of the deprotected hexapeptide as its TFA salt. 0.117 g (0.15 mmol) of this
material was dissolved in 100 ml of abs. THF and subjected to cyclization with
DEPBT (0.14 g, 0.46 mmol) and DIEA (1 ml) according to the GP 5. Reaction
time: 3 d. Purification by CC (CH2Cl2/MeOH 12:1, 2x) and preparative TLC
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(CH2Cl2/MeOH 10:1) afforded 30 mg (35%) of pure 1 as a white powder. M.p.
>280° (dec.) (for data of 1 see 4.2).
4.2. Cyclo(Pro-Aib-Gly-Aib-Aib-Phe) (1) from 13. The N-terminus of 13
(0.4 g, 0.52 mmol) was deprotected according to the GP 3 (H2, 45 mg Pd/C, 10 ml
MeOH) to give 0.328 g (quant. yield) of H-Phe-Pro-Aib-Gly-Aib-Aib-OtBu as a
pale yellow foam. This material was dissolved in 30 ml CH2Cl2/TFA (1:1) and
stirred for 4 h at r.t. Excess TFA was removed as described in 4.1 and 0.404 g
(0.52 mmol, quant. yield) of the deprotected linear precursor was obtained as its
TFA salt, which was used in the cyclization reactions without further purification.
DEPC-mediated cyclization: A soln. of 0.135 g (0.17 mmol) of the above
prepared deprotected hexapeptide in 175 ml of abs. DMF was subjected to
cyclization with DEPC (0.141 g, 0.86 mmol) and DIEA (1.75 ml) according to the
GP 6. Reaction time: 6 d. Purification by CC (CH2Cl2/MeOH 13:1, then
CH2Cl2/MeOH 17:1) afforded 33 mg (34%) of pure 1 as a white foam.
PyAOP-mediated cyclization: A soln. of 0.135 g (0.17 mmol) of the linear
precursor in 220 ml of abs. DMF was subjected to cyclization using PyAOP
(0.361 g, 0.69 mmol) and DIEA (2.2 ml) according to the GP 7. Reaction time: 24
h. Purification by CC (AcOEt/MeOH 10:1, then CH2Cl2/MeOH 15:1) afforded 27
mg (28%) pure 1 as a white foam. In addition, 15 mg of 1 contaminated with
some Et(i-Pr)2NH+PF6- was obtained, but could not be purified by CC. Crystals
suitable for an X-ray crystal structure analysis were obtained from this mixture by
crystallization from AcOEt/EtOH/hexane.
DEPBT-mediated cyclization: A soln. of 0.134 g (0.17 mmol) of the linear
hexapeptide in 175 ml of abs. DMF was subjected to cyclization with DEPBT
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(0.26 g, 0.86 mmol) and DIEA (1.75 ml) according to the GP 5. No cyclic product
was obtained after 3 d reaction time.
Data of cyclo(Pro1-Aib2-Gly3-Aib4-Aib5-Phe6) (1): IR: 3317s, 3061w,
1985m, 2938m, 1665s, 1536s, 1444m, 1385m, 1363m, 1285m, 1216m, 1191m,
1101w, 1019w, 923w, 875w, 825w, 747w, 701w. 1H-NMR: 9.30 (s, NH of Aib2);
8.46 (t-like, NH of Gly3); 7.90 (s, NH of Aib4); 7.42 (d, J = 8.4, NH of Phe6);
7.40-7.31 (m, 2 arom. H of Phe6); 7.25-7.12 (m, NH of Aib5, 3 arom. H of Phe6);
4.58-4.55 (m, CH(2) of Phe6); 4.36-4.33 (m, CH(2) of Pro1); 3.86-3.79 (m, 1H of
CH2 of Gly3, 1H of CH2(5) of Pro1); 3.73-3.66 (m, 1H of CH2 of Gly3, 1H of
CH2(5) of Pro1); 2.86-2.67 (m, CH2 of Phe6); 2.20-2.11 (m, 1H of CH2(3) and 1H
of CH2(4) of Pro1); 1.98-1.93 (m, 1H of CH2(4) of Pro1); 1.89-1.82 (m, 1H of
CH2(3) of Pro1); 1.46, 1.39 (2s, 2 Me of Aib2); 1.35 (s, Me of Aib4); 1.31, 1.30 (2s,
2 Me of Aib5); 1.18 (s, Me of Aib4). 13C-NMR: 176.3 (s, CO of Aib2); 174.4 (s,
CO of Aib5); 173.8 (s, CO of Pro1); 172.5 (s, CO of Aib4); 171.7 (s, CO of Phe6);
170.1 (s, CO of Gly3); 137.3 (s, 1 arom. C of Phe6); 129.3, 128.1, 126.2 (3d, 5
arom. CH of Phe6); 59.7 (d, C(2) of Pro1); 56.1 (s, C(2) of Aib4); 56.0 (s, C(2) of
Aib2); 55.8 (s, C(2) of Aib5); 53.1 (d, C(2) of Phe6); 47.3 (t, C(5) of Pro1); 45.1 (t,
C(2) of Gly3); 36.9 (t, C(3) of Phe6); 28.4 (t, C(3) of Pro1); 27.8 (q, Me of Aib5);
27.4 (q, Me of Aib4); 26.5 (q, Me of Aib2); 24.9 (t, C(4) of Pro1); 23.1 (q, Me of
Aib2); 22.4 (q, Me of Aib4); 22.3 (q, Me of Aib5). ESI-MS (MeOH + NaI): 579
(100, [M+Na]+).
5. Preparation of Z-Gly-Aib-Aib-Phe-Pro-Aib-N(Me)Ph (14).
5.1. Synthesis of 14. Deprotection of the N-terminus of 10 (0.728 g, 1.27
mmol) was performed according to the GP 3 (H2, 80 mg Pd/C, 10 ml MeOH).
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Purification by CC (CH2Cl2/MeOH 10:1) yielded 0.519 g (93%) of H-Phe-Pro-
Aib-N(Me)Ph, which was used directly in the next step.
The above obtained deprotected tripeptide (0.519 g, 1.19 mmol) was dissolved in
10 ml of abs. CH2Cl2 and coupled with Z-Gly-Aib-Aib-OH [5] (0.41 g, 1.08
mmol) using PyAOP (0.573 g, 1.1 mmol), HOAt (0.15 g, 1.1 mmol, 2.2 ml 0.5M
DMF-soln.), and DIEA (0.284 g, 2.2 mmol) according to the GP 4. Reaction time:
20 h. Purification of the crude product by CC (CH2Cl2/MeOH 15:1) yielded 0.78 g
(90%) of pure 14 as a white foam. IR: 3322s, 3061m, 3031m, 2984m, 2937m,
1650s, 1593m, 1522s, 1496s, 1454s, 1385m, 1362m, 1237s, 1172m, 1116m,
1090m, 1048m, 1001w, 922w, 774w, 742m, 702m. 1H-NMR: 8.09, 7.94 (2s, 2
NH); 7.53-7.12 (m, 15 arom. H, 3 NH); 5.02 (s, PhCH2O); 4.65-4.60, 4.25-4.23
(2m, CH(2) of Phe, CH(2) of Pro); 3.68-3.41 (m, CH2 of Gly and CH2(5) of Pro);
3.23 (s, MeN); 3.06-2.81 (m, CH2 of Phe); 1.98-1.78 (m, CH2(3) and CH2(4) of
Pro); 1.35, 1.30, 1.27, 1.23 (4s, 6 Me of Aib). 13C-NMR: 173.8, 172.8, 172.2,
170.4, 169.3, 169.1 (6s, 6 CO); 156.6 (s, CO (urethane)); 145.7, 137.8, 136.9 (3s,
3 arom. C); 129.3, 128.6, 128.2, 127.9, 127.7, 127.5, 127.2, 126.8, 126.2, 126.0
(10d, 15 arom. CH); 66.5 (t, PhCH2O); 59.3 (d, C(2) of Pro); 56.0, 55.8 (2s, 3
C(2) of 3 Aib); 52.3 (d, C(2) of Phe); 46.4, 43.9 (2t, C(2) of Gly and C(5) of Pro);
39.5 (q, MeN); 36.6 (t, C(3) of Phe); 28.6 (t, C(3) of Pro); 26.1, 25.5, 24.7, 24.3
(4q, 6 Me of 3 Aib); 24.2 (t, C(4) of Pro). ESI-MS (MeOH+NaI): 820 (100,
[M+Na]+). Anal. calc. for C43H55N7O8•1/2H2O (806.96): C 64.00, H 6.99, N 12.15;
found: C 63.86, H 6.96, N 12.07.
5.2. Attempted Cyclization of 14. According to the GP 2, a soln. of 14
(0.68 g, 0.85 mmol) in 10 ml of 3N HCl (MeCN/H2O 1:1) was stirred for 15 h.
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Then, the MeCN was evaporated, 2N HCl (5 ml) was added and the product was
extracted with CH2Cl2, dried (Na2SO4), concentrated and dried i.v.: 0.54 g (89%)
of peptide acid were obtained as a white foam. This acid (0.464 g, 0.65 mmol)
was hydrogenated according to the GP 3 (H2, 50 mg Pd/C, 8 ml MeOH) to give
0.358 g (95%) of H-Gly-Aib-Aib-Phe-Pro-Aib-OH as a pale yellow foam, which
was used in the cyclization reactions without further purification.
DEPC-mediated cyclization: 90 mg (0.16 mmol) of the linear hexapeptide was
dissolved in abs. DMF (160 ml) and subjected to cyclization with DEPC (0.128 g,
0.78 mmol) and DIEA (1.6 ml) according to the GP 6. No cyclopeptide 1 was
formed after 3 d reaction time.
DEPBT-mediated cyclization: Following the GP 5, with 90 mg (0.16 mmol) of
the linear peptide dissolved in abs. DMF (100 ml), DEPBT (0.141 g, 0.47 mmol)
and DIEA (1 ml). No cyclic product was obtained after 3 d reaction time.
PyAOP-mediated cyclization: According to the GP 7, with 90 mg (0.16 mmol) of
the linear precursor in abs. DMF (160 ml) and PyAOP (0.328 g, 0.63 mmol),
HOAt (0.63 mmol, 1.4 ml 0.5M DMF-soln.) and DIEA (1.6 ml). No cyclic
product was obtained after 3 d reaction time.
HATU-mediated cyclization: The linear hexapeptide (74 mg, 0.13 mmol) was
dissolved in abs. DMF (130 ml) and cooled to 0° in an ice bath. HATU (54 mg,
0.14 mmol), HOAt (0.14 mmol, 0.3 ml 0.5M DMF-soln.), and collidine (0.157 g,
13 mmol) were then added under stirring. The mixture was allowed to warm to r.t.
over a period of 2 h, and was stirred for a further 3 d. No formation of
cyclopeptide 1 was observed.
6. Synthesis of Cyclo(Gly-Aib-Pro-Gly-Aib-Aib) (2).
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6.1. Fmoc-Pro-Gly-Aib-Aib-N(Me)Ph (15 ). Deprotection of the N-
terminus of 6 (0.4 g, 0.85 mmol) was accomplished by following the GP 3 (H2, 45
mg Pd/C, 10 ml MeOH). The obtained H-Gly-Aib-Aib-N(Me)Ph (0.285 g, quant.
yield) was used directly in the next step without further purification.
Coupling of Fmoc-Pro-OH (0.262 g, 0.78 mmol) with the above prepared N-
deprotected peptide (0.285 g, 0.85 mmol) was performed using PyAOP (0.47 g,
0.9 mmol) and DIEA (0.233 g, 1.8 mmol) in abs. CH2Cl2 (10 ml) according to the
GP 4. Reaction time: 24 h. Purification by CC (AcOEt/MeOH 15:1,
CH2Cl2/MeOH 20:1) yielded 0.47 g (93%) of pure 15 as a white foam. IR: 3748m,
3671m, 3647m, 3419s, 3064m, 2983m, 2934m, 1675s, 1594m, 1524s, 1494s,
1452s, 1423s, 1391m, 1360s, 1339m, 1195m, 1168m, 1124m, 1092m, 1040w,
1022w, 989w, 759m, 740m, 706m. 1H-NMR (CD3OD): 7.81-7.18 (m, 13 arom. H);
4.47-4.20 (m, CHCH2O of Fmoc and CH(2) of Pro); 3.74-3.47 (m, CH2 of Gly and
CH2(5) of Pro); 3.22 (s, MeN); 2.30-1.80 (m, CH2(3) and CH2(4) of Pro); 1.46,
1.45, 1.41, 1.39 (4s, 4 Me of 2 Aib). 13C-NMR (CD3OD): 175.9, 175.3, 171.0 (3s,
4 CO); 157.0 (s, CO(urethane)); 145.1, 142.5 (2s, 5 arom. C); 130.2, 128.8, 128.4,
128.1, 125.9, 120.9 (6d, 13 arom. CH); 68.8 (t, CHCH2O of Fmoc); 62.1 (d, C(2)
of Pro); 58.6, 58.2 (2s, 2 C(2) of 2 Aib); 48.3 (d, CHCH2O of Fmoc); 48.1, 44.6
(2t, C(5) of Pro and C(2) of Gly); 41.2 (q, MeN); 31.1 (t, C(3) of Pro); 26.2, 25.9,
25.3 (3q, 4 Me of 2 Aib); 25.5 (t, C(4) of Pro). ESI-MS (MeOH+NaI): 676 (100,
[M+Na]+), 534 (70, [M-N(Me)Ph]+). Anal. calc. for C37H43N5O6•1/3H2O (659.78):
C 67.36, H 6.67, N 10.61; found: C 67.27, H 6.90, N 10.61.
6.2. Z-Gly-Aib-Pro-Gly-Aib-Aib-N(Me)Ph (16). To a soln. of 15 (0.47 g,
0.72 mmol) in CH2Cl2 (7 ml), Et2NH (5 ml) was added under stirring. After 5 h at
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r.t. the solvents were removed under reduced pressure and the residue was
purified by CC (CH2Cl2/MeOH 10:1) to give 0.253 g (82%) of H-Pro-Gly-Aib-
Aib-N(Me)Ph, which was used directly in the next step.
Coupling of Z-Gly-Aib-OH (0.157 g, 0.53 mmol) with the above-obtained
tripeptide (0.253 g, 0.58 mmol) in abs. CH2Cl2 (10 ml) was carried out using
PyAOP (0.313 g, 0.6 mmol) and DIEA (0.156 g, 1.2 mmol) according to the GP
4. Reaction time: 24 h. The crude product was purified by CC (CH2Cl2/MeOH
15:1) to give 0.33 g (87%) of 16 as a white foam. IR: 3745m, 3418s, 3062m,
2985m, 2936m, 1659s, 1594m, 1529s, 1471m, 1455m, 1395s, 1364m, 1244s,
1171m, 1115m, 1092m, 1053m, 769w, 741w, 706w. 1H-NMR (CD3OD): 7.55-7.24
(m, 10 arom. H); 5.13-5.03 (m, PhCH2O); 4.39-4.34 (m, CH(2) of Pro); 3.92-3.43
(m, 2 CH2 of 2 Gly and CH2(5) of Pro); 3.34 (s, MeN); 2.27-1.74 (m, CH2(3) and
CH2(4) of Pro); 1.52, 1.49, 1.48, 1.47, 1.45 (5s, 6 Me of 3 Aib). 13C-NMR
(CD3OD): 176.2, 175.6, 175.5, 174.9, 172.2, 171.3 (6s , 6 CO); 158.5 (s ,
CO(urethane)); 146.8, 138.0 (2s, 2 arom. C); 130.2, 129.4, 129.1, 128.8, 128.3,
128.1 (6d, 10 arom. CH); 67.7 (t, PhCH2O); 64.5 (d, C(2) of Pro); 58.6, 58.3, 57.7
(3s, 3 C(2) of 3 Aib); 49.7 (t, C(5) of Pro); 44.5, 44.3 (2t, 2 C(2) of 2 Gly); 41.1
(q, MeN); 29.5, 26.8 (2t, C(3) and C(4) of Pro); 26.5, 26.4, 25.0, 23.9 (4q, 6 Me
of 3 Aib). ESI-MS (MeOH+NaI): 730 (100, [M+Na]+). Anal. calc. for
C36H49N7O8•1/2H2O (716.83): C 60.32, H 7.03, N 13.68; found: C 60.27, H 6.99,
N 13.61.
6.3. Z-Gly-Aib-Pro-Gly-Aib-Aib-OH (17). According to the GP 2, 16 (0.25
g, 0.35 mmol) in 4 ml of 3N HCl (MeCN/H2O 1:1) was stirred overnight. The
product was extracted with CH2Cl2, dried (Na2SO4) and evaporated: 0.177 g
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(82%) of pure 17 were obtained as a white foam. IR: 3304s, 3061m, 2986m,
2940m, 1719s, 1657s, 1534s, 1470m, 1455m, 1410m, 1365m, 1243s, 1165s,
1051m, 910w, 777w, 745w, 697m. 1H-NMR (CD3OD): 8.61, 7.99, 7.62 (3br.s, 3
NH); 7.36-7.27 (m, 5 arom. H); 5.14-5.03 (m, PhCH2O); 4.40-4.35 (m, CH(2) of
Pro); 3.92-3.30 (m, CH2(5) of Pro and 2 CH2 of 2 Gly); 2.26-1.73 (m, CH2(3) and
CH2(4) of Pro); 1.50, 1.475, 1.468, 1.46, 1.44 (5s, 6 Me of 3 Aib). 13C-NMR
(CD3OD): 177.9, 176.0, 175.5, 174.9, 172.3, 171.3 (6s , 6 CO); 159.0 (s ,
CO(urethane)); 138.1 (s, 2 arom. C); 129.4, 129.1, 128.8 (3d, 5 arom. CH); 67.7
(t, PhCH2O); 64.4 (d, C(2) of Pro); 58.1, 57.8, 57.1 (3s, 3 C(2) of 3 Aib); 49.7 (t,
C(5) of Pro); 44.3, 44.2 (2t, 2 C(2) of 2 Gly); 29.5, 26.8 (2t, C(3) and C(4) of
Pro); 26.4, 25.9, 25.3, 25.1, 25.0, 23.9 (6q , 6 Me of 3 Aib). ESI-MS
(MeOH+NaI): 641 (100, [M+Na]+). Anal. calc. for C29H42N6O9 (618.69): C 56.29,
H 6.84, N 13.58; found: C 55.98, H 6.68, N 13.46.
6.4. Cyclo(Gly1-Aib2-Pro3-Gly4-Aib5-Aib6) (2). Peptide acid 17 (0.162 g,
0.26 mmol) was hydrogenated according to the GP 3 (H2; 25 mg Pd/C, 6 ml
MeOH) to give 0.125 g (0.26 mmol, quant. yield) of the deprotected hexapeptide
as a pale yellow foam, which was used in the cyclization step without further
purification. According to the GP 6, this material (0.125 g, 0.26 mmol) in abs.
DMF (170 ml) was treated with DEPC (0.168 g, 1.03 mmol) and DIEA (1.7 ml).
Reaction time: 7 d. During the evaporation of DMF, an extremely insoluble white
precipitate formed. This precluded its purification by CC. The precipitate was
collected by filtration and washed with H2O, MeOH and CH2Cl2 in order to
remove excess DEPC and some formed byproducts. Recrystallization from hot
H2O/MeOH/EtOH yielded 43 mg (36%) of pure 2 as a white powder. M.p. >320°
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(dec.). IR: 3487m, 3365m, 3324s, 3283s, 3044w, 2990w, 2937w, 1683s, 1650s,
1598s, 1545s, 1470m, 1418m, 1385m, 1366m, 1337w, 1252m, 1194w, 1178w,
1021w, 944w, 919w, 811w, 705w. 1H-NMR ((D6)DMSO + 3 drops of TFA): 8.78
(s, NH of Aib2); 8.31 (s, NH of Aib5); 7.49 (s, NH of Aib6); 7.42 (br.d, J = 9.4,
NH of Gly4); 7.36 (br.d, J = 9.1, NH of Gly1); 4.67-4.61 (m, CH(2) of Pro3); 4.30
(dd, J = 9.8, 17.5, 1H of CH2 of Gly4); 4.22 (dd, J = 9.2, 17.8, 1H of CH2 of Gly1);
3.73-3.67 (m, 1H of CH2(5) of Pro3); 3.53 (br.d, J = 17.3, 1H of CH2 of Gly1);
3.48-3.35 (m, 1H of CH2 of Gly4 and 1H of CH2(5) of Pro3); 1.99-1.92 (m, 1H of
CH2(3) of Pro3); 1.88-1.79 (m, 1H of CH2(3) and 1H of CH2(4) of Pro3); 1.71-1.62
(m, 1H of CH2(4) of Pro3); 1.45 (s, Me of Aib6); 1.36, 1.34 (2s, 2 Me of Aib2);
1.31 (s, Me of Aib5); 1.27 (br.s, Me of Aib5 and Me of Aib6). 13C-NMR
((D6)DMSO + 3 drops of TFA): 174.1 (s, CO of Aib6); 173.5 (s, CO of Aib5);
171.8 (s, CO of Aib2); 171.1 (s, CO of Pro3); 169.7 (s, CO of Gly4); 169.1 (s, CO
of Gly1); 61.1 (d, C(2) of Pro3); 56.9 (s, C(2) of Aib6); 56.3 (s, C(2) of Aib5); 55.9
(s, C(2) of Aib2); 46.8 (t, C(5) of Pro3); 39.7 (t, C(2) of Gly4); 39.2 (t, C(2) of
Gly1); 28.5 (q, Me of Aib6); 27.7 (t, C(3) of Pro3); 26.4 (q, Me of Aib5); 26.0 (q,
Me of Aib2); 24.3 (t, C(4) of Pro3); 23.4 (q, Me of Aib2); 23.25 (q, Me of Aib5);
23.1 (q, Me of Aib6). ESI-MS (MeOH + NaI): 489 (100, [M+Na]+).
7. Synthesis of Z-Gly-Aib-Pro-Aib-Phe-Aib-OtBu (21).
7.1. Z-Gly-Aib-Pro-Aib-N(Me)Ph (18). A soln. of 4 (0.71 g, 1.39 mmol) in
CH2Cl2 (10 ml) and Et2NH (5 ml) was stirred for 3 h at r.t. The solvents were then
removed under reduced pressure and the crude N-deprotected peptide was purified
by CC (CH2Cl2/MeOH/NH3(l) 10:1:0.1) to give 0.322 g (80%) H-Pro-Aib-
N(Me)Ph, which was used directly in the next step.
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The coupling of this dipeptide (0.23 g, 0.79 mmol) with Z-Gly-Aib-OH
(0.213 g, 0.72 mmol) in abs. CH2Cl2 (6 ml) and abs. MeCN (2 ml) was
accomplished using PyAOP (0.417 g, 0.8 mmol) and DIEA (0.206 g, 1.6 mmol)
according to the GP 4. Reaction time: 18 h. Purification by CC (CH2Cl2/MeOH
20:1, 2x) yielded 0.385 g (94%) 18 as a white foam. IR: 3423s, 3299s, 3062m,
3037m, 2985m, 2939m, 2878w, 1722s, 1647s, 1594m, 1534s, 1495s, 1470m,
1454m, 1399s, 1363s, 1242s, 1212m, 1168m, 1115m, 1090m, 1051m, 927w,
769w, 741w. 1H-NMR: 8.53, 7.58 (2s, 2 NH); 7.49 (t, J = 6.1, NH of Gly); 7.39-
7.15 (m, 10 arom. H); 5.10-4.96 (m, PhCH2O); 4.33-4.28 (m, CH(2) of Pro); 3.84,
3.78 (2d, J = 6.3, CH2 of Gly); 3.67-3.45 (m, CH2(5) of Pro); 3.26 (s, MeN); 2.09-
1.60 (m, CH2(3) and CH2(4) of Pro); 1.40, 1.37, 1.36, 1.32 (4s, 4 Me of 2 Aib).
13C-NMR: 172.5, 171.4, 170.8, 169.1 (4s, 4 CO); 156.4 (s, CO(urethane)); 146.1,
136.8 (2s, 2 arom. C); 128.5, 128.2, 127.7, 127.5, 126.7, 125.7 (6d, 10 arom. CH);
65.3 (t, PhCH2O); 61.5 (d, C(2) of Pro); 55.7, 55.6 (2s, 2 C(2) of 2 Aib); 47.4,
42.6 (2t, C(5) of Pro and C(2) of Gly); 39.1 (q, MeN); 28.2 (t, C(3) of Pro); 25.7,
25.5, 25.2, 23.8 (4q, 4 Me of 2 Aib); 25.1 (t, C(4) of Pro). ESI-MS (MeOH+NaI):
588 (100, [M+Na]+). Anal. calc. for C30H39N5O6•1/3H2O (571.67): C 63.03, H
6.99, N 12.25; found: C 63.04, H 6.91, N 12.28.
7.2. Z-Gly-Aib-Pro-Aib-OH (19). According to the GP 2, with 0.47 g (0.83
mmol) of 18 in 3N HCl (MeCN/H2O 1:1) (10 ml), stirred for 24 h. The product
was extracted from the mixture with CH2Cl2, dried (Na2SO4), and concentrated.
Purification by CC (CH2Cl2/MeOH 11:1) yielded 0.26 g (66%) of 19 as a white
foam. IR: 3415s, 3311s, 3063m, 2986s, 2942s, 1723s, 1657s, 1536s, 1470m,
1455m, 1406s, 1365s, 1343m, 1245s, 1161s, 1051m, 977w, 931w, 778w, 741m,
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698m. 1H-NMR (CD3OD): 7.97, 7.78 (2s, 2 NH); 7.34-7.28 (m, 5 arom. H, NH);
5.13-5.01 (m, PhCH2O); 4.41-4.37 (m, CH(2) of Pro); 3.90-3.57 (m, CH2 of Gly
and CH2(5) of Pro); 2.14-1.81 (m, CH2(3) and CH2(4) of Pro); 1.48, 1.45, 1.41 (3s,
4 Me of 2 Aib). 13C-NMR (CD3OD): 178.5, 174.4, 173.7, 171.2 (4s, COOH, CO);
159.0 (s, CO(urethane)); 67.7 (t, PhCH2O); 63.8 (d, C(2) of Pro); 57.6, 57.1 (2s, 2
C(2) of 2 Aib); 49.5, 44.2 (2t, C(5) of Pro and C(2) of Gly); 29.5, 26.4 (2t, C(3)
and C(4) of Pro); 26.1, 26.0, 24.5, 24.3 (4q , 4 Me of 2 Aib). ESI-MS
(MeOH+NaI): 499 (100, [M+Na]+). Anal. calc. for C23H32N4O7•1/3H2O (482.53):
C 57.25, H 6.82, N 11.61; found: C 57.28, H 6.72, N 11.37.
7.3. Z-Gly-Aib-Pro-Aib-Phe-Aib-OtBu (21). Z-Phe-Aib-OtBu (20 [15],
0.25 g, 0.57 mmol) was hydrogenated according to the GP 3 (H2, 30 mg Pd/C, 10
ml MeOH). Reaction time: 24 h. Purification by CC (AcOEt/MeOH 12:1) yielded
0.168 g (97%) of the N-deprotected dipeptide, which was used directly in the next
step.
The coupling of 19 (0.24 g, 0.5 mmol) with the above prepared dipeptide
H-Phe-Aib-OtBu (0.168 g, 0.55 mmol) in abs. CH2Cl2 (8 ml) and abs. MeCN (2
ml) was performed using PyAOP (0.262 g, 0.55 mmol) and DIEA (0.129 g, 1.0
mmol) according to the GP 4. Reaction time: 20 h. Purification by CC
(AcOEt/MeOH 15:1), followed by prep. TLC (AcOEt/MeOH 16:1) yielded 0.213
g (56%) of 21 as a white foam. IR: 3314s, 3030w, 2983m, 2935m, 2878w, 1729s,
1662s, 1623s, 1533s, 1470m, 1455m, 1409m, 1384m, 1366m, 1271m, 1248m,
1148s, 1050m, 980w, 940w, 849w, 754m, 699m. 1H-NMR (CD3OD): 7.70, 7.62,
7.57 (3s, 3 NH); 7.34-7.12 (m, 10 arom. H, 2 NH); 5.08 (br.s, PhCH2O); 4.55-
4.45, 4.25-4.18 (2m, CH(2) of Pro and CH(2) of Phe); 3.95-3.52 (m, CH2 of Gly
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and CH2(5) of Pro); 3.43-3.34 (m, 1H of CH2 of Phe); 2.90-2.80 (m, 1H of CH2 of
Phe); 2.30-1.60 (m, CH2(3) and CH2(4) of Pro); 1.54, 1.47, 1.46, 1.45, 1.37, 1.12
(6s, 6 Me of 3 Aib and Me3C). 13C-NMR (CD3OD): 177.3, 177.2, 175.0, 174.8,
172.8, 171.2 (6s, 6 CO); 159.1 (s, CO(urethane)); 139.3, 138.0 (2s, 2 arom. C);
130.0, 129.4, 129.2, 129.0, 128.7, 127.4 (6d, 10 arom. CH); 81.7 (s, Me3C); 67.6
(t, PhCH2O); 65.4 (d, C(2) of Pro); 58.0, 57.6, 57.5 (3s, 3 C(2) of 3 Aib); 56.3 (d,
C(2) of Phe); 50.0, 44.0 (2t, C(5) of Pro and C(2) of Gly); 38.4 (t, C(3) of Phe);
29.7 (t, C(3) of Pro); 28.2 (q, Me3C); 26.9 (t, C(4) of Pro); 27.2, 26.8, 25.7, 24.7,
23.84, 23.77 (6q, 6 Me of 3 Aib). ESI-MS (MeOH+NaI): 788 (100, [M+Na]+).
Anal. calc. for C40H56N6O9•1/2H2O (773.93): C 62.08, H 7.42, N 10.86; found: C
62.19, H 7.55, N 10.85.
7.4. Attempted Cyclization of 21. The N-terminus of 21 (0.193 g, 0.25
mmol) was deprotected according to the GP 3 (H2, 25 mg Pd/C, 6 ml MeOH):
0.145 g (0.23 mmol, 91%) H-Gly-Aib-Pro-Aib-Phe-Aib-OtBu were obtained after
purification by CC (CH2Cl2/MeOH/NH3(l) 10:1:0.1) as a white foam. This peptide
was dissolved in CH2Cl2/TFA (20 ml) at r.t. and stirred for 5 h. Excess TFA was
removed as described in section 4.1 and, after drying i.v., 0.19 g (0.23 mmol,
quant. yield) of the deprotected hexapeptide was obtained as its TFA salt.
DEPBT-mediated cyclization: According to the GP 5, a soln. of the linear peptide
(91 mg, 0.11 mmol) in abs. DMF (80 ml) was subjected to cyclization with
DEPBT (0.137 g, 0.46 mmol) and DIEA (0.8 ml). No cyclopeptide 22 was
obtained after 3 d reaction time.
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PyBOP-mediated cyclization: Following the GP 7, with 91 mg (0.11 mmol) of the
linear precursor in abs. DMF (230 ml), PyBOP (0.18 g, 0.34 mmol) and DIEA
(2.3 ml). No cyclic product was formed after 3 d reaction time.
8. Synthesis of Fmoc-Pro-Aib-Gly-Aib-Phe-Aib-N(Me)Ph (27).
8.1. Fmoc-Pro-Aib-Gly-Aib-N(Me)Ph (24). The N-terminus of 23 (0.385 g,
1.0 mmol) was deprotected (H2, 40 mg Pd/C, 6 ml MeOH) according to the GP 3:
0.25 g (quant. yield) of H-Gly-Aib-N(Me)Ph were obtained as a pale yellow foam
and used directly in the next coupling step.
Following GP 4, a soln. of 5 (0.385 g, 0.91 mmol) and the above-prepared
dipeptide (0.25 g, 1.0 mmol) in abs. CH2Cl2 (6 ml) and abs. DMF (2 ml) was
treated with HATU (0.38 g, 1.0 mmol), HOAt (0.136 g, 1.0 mmol, 2 ml 0.5M
DMF-soln.) and DIEA (0.258 g, 2.0 mmol). Reaction time: 24 h. Purification by
CC (CH2Cl2/MeOH 15:1, then AcOEt/MeOH 12:1) afforded 0.45 g (76%) of 24
as a white foam. IR: 3423s, 3063m, 2982m, 2932m, 1670s, 1593m, 1537s, 1495s,
1468m, 1451s, 1423s, 1389m, 1359s, 1337m, 1284m, 1244m, 1192m, 1171m,
1122m, 1091m, 1022w, 991w, 874w, 760m, 741m, 704m. 1H-NMR (CDCl3): 7.76,
7.74 (2br.s, 2 NH); 7.58-7.20 (m, 13 arom. H); 6.84 (br.s, NH); 4.42-4.08 (m,
CHCH2O of Fmoc, CH(2) of Pro); 3.86-3.48 (m, CH2(5) of Pro and CH2 of Gly);
3.26 (s, MeN); 2.08-1.80 (m, CH2(3) and CH2(4) of Pro); 1.50, 1.47, 1.42 (3s, 4
Me of 2 Aib). 13C-NMR (CDCl3): 173.5, 173.0, 172.5, 168.4 (4s, 4 CO); 156.0 (s,
CO(urethane)); 145.1, 143.5, 141.2 (3s, 5 arom. C); 129.0, 127.7, 127.3, 127.1,
127.0, 124.9, 119.9 (7d, 13 arom. CH); 67.9 (t, CHCH2O of Fmoc); 61.0 (d, C(2)
of Pro); 57.25, 57.20 (2s, 2 C(2) of 2 Aib); 47.1 (t, C(5) of Pro); 46.9 (d, CHCH2O
of Fmoc); 43.3 (t, C(2) of Gly); 40.4 (q, MeN); 29.1 (t, C(3) of Pro); 26.6, 26.1,
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24.5 (3q, 4 Me of 2 Aib); 24.7 (t, C(4) of Pro). ESI-MS (MeOH+NaI): 676 (100,
[M+Na]+). Anal. calc. for C37H43N5O6•1/2H2O (662.78): C 67.05, H 6.69, N 10.56;
found: C 67.10, H 6.63, N 10.50.
8.2. Fmoc-Pro-Aib-Gly-Aib-OH (25). According to GP 2, a soln. of 24
(0.387 g, 0.59 mmol) in 6 ml of 3N HCl (MeCN/H2O 1:1) was stirred for 20 h.
Purification by CC (CH2Cl2/MeOH 10:1) yielded 0.247 g (74%) of 25 as a white
foam. IR: 3319s, 3066m, 2984m, 2940m, 2882m, 1673s, 1539s, 1470m, 1451s,
1427s, 1390m, 1357m, 1337m, 1286m, 1244m, 1213m, 1167m, 1127m, 1091m,
1043w, 1020w, 989w, 939w, 915w, 876w, 759m, 740m. 1H-NMR: 8.62 (s, NH);
7.90-7.88 (m, 2 arom. H); 7.78 (t, J = 5.9, NH of Gly); 7.71-7.31 (m, 6 arom. H,
NH); 4.43-4.14 (m, CHCH2O of Fmoc, CH(2) of Pro); 3.67-3.32 (m, CH2 of Gly,
CH2(5) of Pro); 2.30-1.80 (m, CH2(3) and CH2(4) of Pro); 1.37, 1.33, 1.31, 1.28
(4s, 4 Me of 2 Aib). 13C-NMR: 175.1, 173.7, 172.7, 168.1 (4s, 4 CO); 154.2 (s,
CO(urethane)); 143.7, 143.5, 140.6 (3s, 4 arom. C); 127.5, 127.0, 125.3, 125.2,
125.0, 120.0 (6d, 8 arom. CH); 66.6 (t, CHCH2O of Fmoc); 59.6 (d, C(2) of Pro);
55.9, 54.5 (2s, 2 C(2) of 2 Aib); 47.1 (t, C(5) of Pro); 46.5 (d, CHCH2O of Fmoc);
42.6 (t, C(2) of Gly); 29.3 (t, C(3) of Pro); 25.6, 24.7, 24.4, 24.3 (4q, 4 Me of 2
Aib); 24.0 (t, C(4) of Pro). ESI-MS (MeOH+NaI): 587 (100, [M+Na]+), 565 (15,
[M+H]+). Anal. calc. for C30H36N4O7•1/2H2O (573.65): C 62.81, H 6.50, N 9.77;
found: C 62.70, H 6.57, N 9.77.
8.3. Fmoc-Pro-Aib-Gly-Aib-Phe-Aib-N(Me)Ph (27). Prior to coupling, Z-
Phe-Aib-N(Me)Ph (26) [16] (0.515 g, 1.09 mmol) was hydrogenated according to
the GP 3 (H2, 60 mg Pd/C, 10 ml MeOH). Purification by CC (AcOEt/MeOH
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15:1) yielded 0.365 g (99%) H-Phe-Aib-N(Me)Ph as a white foam, which was
used directly in the next step.
The coupling of 25 (0.198 g, 0.35 mmol) with the above-prepared
dipeptide (0.13 g, 0.38 mmol) in abs. CH2Cl2 (8 ml) and abs. MeCN (2 ml) was
performed using TBTU (0.128 g, 0.4 mmol), HOBt (0.054 g, 0.4 mmol) and
DIEA (0.103 g, 0.8 mmol) according to the GP 4. Reaction time: 48 h.
Purification by CC (CH2Cl2/MeOH 20:1, then AcOEt/MeOH/hexane 8:1:0.5)
yielded 0.237 g (76%) of 27 as a white foam. IR: 3423s, 3060m, 3025m, 2980m,
2936m, 1665s, 1594m, 1533s, 1496s, 1470m, 1453s, 1424m, 1386m, 1361m,
1338m, 1277m, 1244m, 1191m, 1121m, 1091m, 758w, 741m , 704m . 1H-NMR
(CD3OD): 7.81-7.78, 7.62-7.59, 7.41-7.06 (3m, 18 arom. H, 5 NH); 4.42-4.17 (m,
CHCH2O of Fmoc, CH(2) of Phe and CH(2) of Pro); 3.74-3.45 (m, CH2 of Gly,
CH2(5) of Pro and 1H of CH2 of Phe); 3.26 (s, MeN); 2.98-2.80 (m, 1H of CH2 of
Phe); 2.20-1.80 (m, CH2(3) and CH2(4) of Pro); 1.50, 1.49, 1.45, 1.43, 1.27, 1.11
(6s, 6 Me of 3 Aib). 13C-NMR (CD3OD): 178.0, 176.3, 175.3, 174.9, 172.5, 171.9
(6s, 6 CO); 157.0 (s, CO(urethane)); 146.6, 145.3, 145.1, 142.5, 139.2 (5s, 6
arom. C); 130.3, 129.2, 128.8, 128.1, 127.4, 126.1, 126.0, 121.0 (8d, 18 arom.
CH); 68.8 (t, CHCH2O of Fmoc); 61.9 (d, C(2) of Pro); 58.3, 57.9, 57.7 (3s, 3
C(2) of 3 Aib); 61.9, 56.4 (2d, C(2) of Pro and C(2) of Phe); 48.3 (d, CHCH2O of
Fmoc); 48.1, 45.2 (2t, C(5) of Pro and C(2) of Gly); 41.2 (q, MeN); 37.7 (t, C(3)
of Phe); 31.0 (t, C(3) of Pro); 26.6, 25.6, 25.2 (3q, 6 Me of 3 Aib); 25.5 (t, C(4) of
Pro). ESI-MS (MeOH+NaI): 909 (100, [M +Na]+). Anal. calc. for
C50H59N7O8•1/3H2O (892.06): C 67.32, H 6.74, N 10.99; found: C 67.32, H 6.78,
N 11.04.
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8.4. Attempted Cyclization of 27. According to the GP 2, a soln. of 27
(0.222 g, 0.25 mmol) in 4 ml of 3N HCl (MeCN/H2O 1:1) was stirred for 24 h.
The product was extracted from the mixture with CH2Cl2, dried (Na2SO4), and
concentrated: 0.195 g (98%) peptide acid was obtained as a white foam after
drying i.v. This acid was then dissolved in CH2Cl2 (5 ml) and Et2NH (1 ml) was
added. After 4 h of stirring at r.t., the solvents were removed under reduced
pressure. The product was triturated with Et2O, collected by filtration and washed
with Et2O to give 0.13 g (93%) of deprotected hexapeptide as a pale yellow foam,
which was used in the cyclization without further purification.
This peptide (0.13 g, 0.23 mmol) was dissolved in 450 ml of abs. CH2Cl2/DMF
(2:1) and subjected to cyclization with PyAOP (0.59 g, 1.13 mmol), HOAt (1.13
mmol, 2.5 ml 0.5M DMF-soln.) and DIEA (4.5 ml) by following the GP 7. No
cyclic product was obtained after 3 d reaction time. By purification on Sephadex
LH-20 , eluting with MeOH, 90 mg (0.16 mmol) of starting material was
recovered. The recovered linear peptide (90 mg, 0.16 mmol) was then dissolved in
abs. DMF (160 ml) and subjected to cyclization according to the GP 5, using
DEPBT (0.233 g, 0.78 mmol) and DIEA (1.6 ml). No cyclic product was formed
after 3 d reaction time.
9. Synthesis of Z-Gly-Aib-Aib-Pro-Aib-Aib-OtBu (30).
9.1. Fmoc-Pro-Aib-Aib-OtBu (29). According to the GP 4, the coupling of
5 (0.414 g, 0.98 mmol) with HCl•H-Aib-OtBu (0.211 g, 1.08 mmol) was carried
out in abs. CH2Cl2 (8 ml) and abs. MeCN (2 ml) using PyBOP (0.51 g, 0.98
mmol) and DIEA (0.388 g, 3.0 mmol). Reaction time: 24 h. Purification by CC
(CH2Cl2/MeOH 35:1, then AcOEt/hexane 2:1) afforded 0.459 g (83%) of pure 29.
40
White powder. M.p. 153-154°. IR: 3416m , 3281m , 3041w, 2981m, 2942m,
2876m, 1731s, 1710s, 1687s, 1648s, 1530s, 1470m, 1450s, 1416s, 1389m, 1360s,
1331m, 1307m, 1242m, 1152s, 1097m, 1033w, 991w, 939w, 855w, 760m, 739m.
1H-NMR: 8.21 (s, NH); 7.91-7.89 (m, 2 arom. H); 7.64-7.61 (m, 2 arom. H); 7.43-
7.32 (m, 4 arom. H); 7.20 (s, NH); 4.32-4.13 (m, CHCH2O of Fmoc and CH(2) of
Pro); 3.47-3.38 (m, CH2(5) of Pro); 2.20-1.80 (m, CH2(3) and CH2(4) of Pro);
1.37, 1.32, 1.31, 1.22 (4s, 4 Me of 2 Aib and Me3C). 13C-NMR: 172.7, 171.2 (2s,
3 CO); 154.1 (s, CO(urethane)); 143.6, 143.5, 140.6 (3s, 4 arom. C); 127.6, 127.0,
124.9, 120.0 (4d, 8 arom. CH); 79.0 (s, Me3C); 66.5 (t, CHCH2O of Fmoc); 59.8
(d, C(2) of Pro); 55.7, 55.2 (2s, 2 C(2) of 2 Aib); 46.5 (d, CHCH2O of Fmoc);
46.4 (t, C(5) of Pro); 29.4 (t, C(3) of Pro); 27.3 (q, Me3C); 26.2, 24.8, 23.7, 23.6
(4q, 4 Me of 2 Aib); 24.0 (t, C(4) of Pro). ESI-MS (MeOH+NaI): 586 (100,
[M+Na]+). Anal. calc. for C32H41N3O6 (563.69): C 68.18, H 7.33, N 7.45; found: C
67.85, H 7.34, N 7.41.
9.2. Z-Gly-Aib-Aib-Pro-Aib-Aib-OtBu (30). Prior to coupling, 29 (0.382 g,
0.68 mmol) was deprotected with Et2NH (1 ml) in CH2Cl2 (5 ml) by stirring for 6
h. The solvents were then removed under reduced pressure and the residue
purified by CC (CH2Cl2/MeOH/NH3(l) 11:1:0.1) to afford 0.172 g (74%) of H-
Pro-Aib-Aib-OtBu, which was used directly in the next step.
A soln. of Z-Gly-Aib-Aib-OH (0.19 g, 0.5 mmol) and the above-prepared
tripeptide (0.172 g, 0.5 mmol) in abs. MeCN (8 ml) was treated with PyBOP (0.29
g, 0.56 mmol) and DIEA (0.143 g, 1.1 mmol) according to the GP 4. Reaction
time: 24 h. Purification by CC (AcOEt/MeOH 10:1, then CH2Cl2/MeOH 15:1)
yielded 0.248 g (64%) pure 30 as a white foam. IR: 3336s, 3033m, 2983s, 2937m,
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2877w, 1658s, 1627s, 1521s, 1469s, 1455s, 1413m , 1384m, 1366m, 1305m,
1276s, 1234s, 1148s, 1048m , 987w , 939w , 850w , 751w , 698m . 1H-NMR
(CD3OD): 7.54 (br.s, NH); 7.36-7.28 (m, 5 arom. H, 4 NH); 5.13 (br.s, PhCH2O);
4.20 (t, J = 7.9, CH(2) of Pro); 3.71-3.62 (m, CH2 of Gly and CH2(5) of Pro);
2.30-1.65 (m, CH2(3) and CH2(4) of Pro); 1.51, 1.49, 1.45, 1.42, 1.40 (5s, 8 Me of
4 Aib and Me3C). 13C-NMR (CD3OD): 176.3, 176.0, 175.3, 174.9, 174.4, 171.6
(6s, 6 CO); 159.0 (s, CO(urethane)); 138.2 (s, 1 arom. C); 129.5, 128.9, 128.4 (3d,
5 arom. CH); 81.5 (s, Me3C); 67.6 (t, PhCH2O); 64.8 (d, C(2) of Pro); 57.9, 57.8,
57.45, 57.36 (4s, 4 C(2) of 4 Aib); 49.7, 45.5 (2t, C(5) of Pro and C(2) of Gly);
29.7 (t, C(3) of Pro); 28.1 (q, Me3C); 26.9 (t, C(4) of Pro); 27.4, 25.9, 25.3, 24.2,
24.1 (6s, 8 Me of 4 Aib). ESI-MS (MeOH+NaI): 741 (15, [M+K]+), 725 (100,
[M+Na]+), 703 (100, [M+H]+). Anal. calc. for C35H54N6O9•1/2 H2O (708.85): C
59.30, H 7.77, N 11.85; found: C 59.07, H 7.78, N 11.83.
9.3. Attempted Cyclization of 30. According to the GP 3 (H2, 20 mg Pd/C,
6 ml MeOH), the N-terminus of  30 (0.188 g, 0.27 mmol) was deprotected to give,
after purification by CC (CH2Cl2/MeOH/NH3(l) 11:1:0.1), 0.146 g (97%) H-Gly-
Aib-Aib-Pro-Aib-Aib-OtBu as a white foam. This foam was then dissolved in 22
ml of CH2Cl2/TFA (1:1) and stirred for 5 h at r.t. Excess TFA was removed as
described in section 4.1 and 0.17 g (0.26 mmol) of deprotected hexapeptide was
obtained as its TFA salt after drying i.v.. This material (0.26 mmol) was dissolved
in 170 ml abs. DMF and subjected to cyclization with DEPBT (0.308 g, 1.03
mmol) and DIEA (1.7 ml) by following the GP 5. No reaction was observed after
3 d, and the linear precursor (not as its TFA salt) was fully recovered from the
mixture by purification on Sephadex LH-20, eluting with MeOH. The peptide
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(0.134 g, 0.26 mmol) was then subjected to cyclization with DEPC (0.17 g, 1.04
mmol) and DIEA (1.9 ml) in 190 ml abs. DMF according to the GP 6. However,
no cyclic product was formed after 10 d reaction time.
10. Synthesis of Z-Phe-Pro-Aib-Pro-Aib-Aib-N(Me)Ph (33).
10.1. Fmoc-Pro-Aib-Aib-N(Me)Ph (32). According to the GP 1, 5 (0.484
g, 1.14 mmol) in THF (15 ml) was treated with 3 (0.22 g, 1.26 mmol) in THF (1
ml). Reaction time: 6 d. Purification by CC (AcOEt → AcOEt/MeOH 10:1) gave
0.475 g (70%) of 32. White powder. M.p. 151.0-151.8°. IR: 3384s, 3303s, 3062w,
3039w, 2983m, 2945m, 2890w, 1712s, 1689s, 1648s, 1594m, 1539s, 1494s,
1450s, 1423s, 1392m, 1360s, 1334m, 1285m, 1242m, 1215m, 1203m, 1165m,
1122m, 1088m , 1033w , 1022w , 991w , 877w , 759m , 740m , 707m . 1H-NMR
(CDCl3): 7.77-7.19 (m, 13 arom. H, NH); 6.83 (br.s, NH); 4.42-4.17 (m, CHCH2O
of Fmoc, CH(2) of Pro); 3.64-3.47 (m, CH2(5) of Pro); 3.24 (s, MeN); 2.20-1.89
(m, CH2(3) and CH2(4) of Pro); 1.48, 1.45, 1.42, 1.41 (4s, 4 Me of 2 Aib). 13C-
NMR (CDCl3): 173.5, 172.6, 171.1 (3s, 3 CO); 156.4 (s, CO(urethane)); 144.5,
143.7, 141.2 (3s, 5 arom. C); 129.2, 128.0, 127.7, 127.0, 124.9, 119.9 (6d, 13
arom. CH); 67.6 (t, CHCH2O of Fmoc); 61.2 (d, C(2) of Pro); 58.1, 57.4 (2s, 2
C(2) of 2 Aib); 47.1 (d, CHCH2O of Fmoc); 46.9 (t, C(5) of Pro); 41.0 (q, MeN);
28.7 (t, C(3) of Pro), 25.4, 24.7 (2q, 4 Me of 2 Aib); C(4) of Pro not detectable.
ESI-MS (MeOH+NaI): 619 (100, [M+Na]+). Anal. calc. for C35H40N4O5 (596.73):
C 70.45, H 6.76, N 9.39; found: C 70.35, H 6.75, N 9.32.
10.2. Z-Phe-Pro-Aib-Pro-Aib-Aib-N(Me)Ph (33). The Fmoc group of 32
(0.375 g, 0.63 mmol) was removed with Et2NH (2 ml) in CH2Cl2 (8 ml) as
described in section 9.2. Reaction time: 5 h. Purification by CC
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(CH2Cl2/MeOH/NH3(l) 12:1:0.1) yielded 0.22 g (94%) of N-deprotected tripeptide
as a white foam which was used directly in the next step.
The coupling of 11 (0.257 g, 0.53 mmol) with the above-prepared H-Pro-
Aib-Aib-N(Me)Ph (0.22 g, 0.59 mmol) was accomplished using HATU (0.223 g,
0.59 mmol), HOAt (80 mg, 0.59 mmol, 1.2 ml of 0.5M DMF-soln.) and DIEA
(0.142 g, 1.07 mmol) in MeCN (6 ml) according to the GP 4. Reaction time: 24 h.
Purification by CC (AcOEt/MeOH 12:1) yielded 0.312 g (70%) 33 as a white
foam. IR: 3422s, 3321s, 3061w, 3030m, 2983m, 2940m, 2876m, 1718s, 1659s,
1594m, 1532s, 1496s, 1453s, 1416s, 1391m, 1362m, 1282m, 1244m, 1213m,
1173m, 1089m , 1053m , 1028m , 925w , 880w , 767w , 749w , 702m . 1H-NMR
(CD3OD): 7.78, 7.68 (2br.s, 2 NH); 7.36.7.19 (m, 15 arom. H, 2 NH); 4.99 (br.s,
PhCH2O); 4.64-4.13 (m, CH(2) of Phe, 2 CH(2) of 2 Pro); 3.94-3.38 (m, 2 CH2(5)
of 2 Pro); 3.33 (br.s, MeN); 3.04-2.71 (m, CH2 of Phe); 2.27-1.67 (m, 2 CH2(3)
and 2 CH2(4) of 2 Pro); 1.54, 1.52, 1.50, 1.49, 1.45 (5s, 6 Me of 3 Aib). 13C-NMR
(CD3OD): 176.6, 175.6, 174.7, 174.5, 173.7, 172.6 (6s , 6 CO); 158.2 (s ,
CO(urethane)); 146.9, 138.1, 137.6 (3s, 3 arom. C); 130.2, 130.1, 129.4, 129.3,
128.9, 128.6, 128.1, 127.9, 127.7 (9d, 15 arom. CH); 67.5 (t, PhCH2O); 64.8, 61.4
(2d, 2 C(2) of 2 Pro); 58.4, 58.3, 57.6 (3s, 3 C(2) of 3 Aib); 55.7 (d, C(2) of Phe);
49.8, 48.6 (2t, 2 C(5) of 2 Pro); 41.0 (q, MeN); 38.3 (t, C(3) of Phe); 30.5, 29.6
(2t, 2 C(3) of 2 Pro); 27.2 (q, Me of Aib); 27.0 (t, C(4) of Pro); 26.3, 26.2 (2q, 2
Me of Aib); 26.1 (t, C(4) of Pro); 26.0, 24.9, 24.4 (3q, 3 Me of Aib). ESI-MS
(MeOH+NaI): 861 (100, [M+Na]+).
10.3. Attempted Cyclization of 33. Hexapeptide 33 (0.255 g, 0.3 mmol)
was hydrolyzed according to the GP 2 with 4 ml of 3N HCl (MeCN/H2O 1:1).
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Reaction time: 5 h. The product was extracted with CH2Cl2, dried (Na2SO4),
concentrated and dried u.h.v. to give 0.212 g (93%) of peptide acid as a white
foam, which was used in the next step without further purification. The Z
protecting group was then removed according to the GP 3 (H2, 23 mg Pd/C, 10 ml
MeOH). Reaction time: 16 h; 0.172 g of the deprotected linear precursor were
obtained as a pale yellow foam.
A soln. of 86 mg (0.14 mmol) of the above-prepared linear precursor in
140 ml of abs. DMF was subjected to cyclization with PyAOP (0.292 g, 0.56
mmol), HOAt (0.56 mmol, 1.2 ml 0.5M DMF-soln.) and DIEA (1.4 ml) according
to the GP 7. No cyclic product 34 was obtained after 3 d reaction time.
The linear precursor (86 mg, 0.14 mmol) was dissolved in abs. DMF (140
ml) under stirring. The mixture was cooled to 0° and EDCI•HCl (0.134 g, 0.7
mmol), HOAt (0.7 mmol, 1.4 ml 0.5M DMF-soln.) and DIEA (1.4 ml) were
added. After 2 h at 0°, the mixture was warmed to r.t. and stirred for an additional
3 d. No cyclic product 34 could be isolated.
11. X-Ray Crystal-Structure Determination of 1•Et(i-Pr)2NH+PF6-•H2O
(see Table 3 and Figure 1)4). All measurements were made on a Nonius
KappaCCD area-detector diffractometer [24] using graphite-monochromated
MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 700
cooler. Data reduction was performed with HKL Denzo and Scalepack [25]. The
                                                 
4) CCDC-246353 contains the supplementary crystallographic data for this paper. These data can
be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge
Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033;
e-mail: deposit@ccdc.cam.ac.uk).
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intensities were corrected for Lorentz and polarization effects, but not for
absorption. Data collection and refinement parameters are given in Table 3, and a
view of the molecule is shown in Figure 1. The structure was solved by direct
methods using SIR92 [26], which revealed the positions of all non-H-atoms. The
asymmetric unit contains one molecule of the peptide 1, one H2O molecule and
one unit of ethyl(diisopropyl)ammonium hexafluorophosphate. The PF6- anion is
highly disordered. Three sets of P- and F-atoms were defined for this anion and
refinement of the site occupation factors of each set led to values of 0.648(3),
0.157(4) and 0.195(4). The P-F and F…F distances were restrained tightly, so as to
maintain octahedral geometry and uniform P-F bond lengths. Finally, neighboring
atoms within and between each conformation of the disordered cation and anion
were restrained to have similar atomic displacement parameters. The non-H-
atoms were refined anisotropically. The H-atoms of the H2O molecule were
placed in the positions indicated by a difference electron density map and their
positions were allowed to refine together with individual isotropic displacement
parameters, while restraining the O-H and H…H distances to reasonable values.
All remaining H-atoms were placed in geometrically calculated positions and
refined using a riding model where each H-atom was assigned a fixed isotropic
displacement parameter with a value equal to 1.2Ueq of its parent atom (1.5Ueq for
the Me groups). Refinement of the structure was carried out on F2 using full-
matrix least-squares procedures, which minimised the function Σw(Fo2-Fc2)2. A
correction for secondary extinction was applied. Nine reflections, whose
intensities were considered to be extreme outliers, were omitted from the final
refinement. The absolute configuration of the peptide molecule could not be
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confirmed crystallographically, as refinement of the absolute structure factor
yielded an inconclusively imprecise value of 0.08(15). Therefore, all equivalent
reflections, including the Friedel pairs, were merged and the peptide enantiomer
used in the refinement was chosen to give the S-configuration at each chiral centre
in the peptide molecule which was known from the synthesis of the compound.
Neutral atom scattering factors for non-H-atoms were taken from [27], and those
for H-atoms were taken from [28]. Anomalous dispersion effects were included in
Fc [29]; the values for f’ and f’’ were those of [30]. The values of the mass
attenuation coefficients are those of [31]. All calculations were performed using
the SHELXL97 program [32].
In 1, each NH group of the peptide molecule acts as a donor for H-bonds.
Two of the interactions, N(1)-H and N(10)-H, are intramolecular H-bonds with
the amide O-atoms that are diagonally opposed in the peptide ring. Each of these
interactions has the graph set motif [33] of S(10). This corresponds with the usual
spacing along the peptide chain between the donor and acceptor atoms in open
chain peptide turns. N(7)-H forms a H-bond with an F-atom in each of the
disordered orientations of the PF6- anion; graph set motif D. N(13)-H forms an
intermolecular H-bond with the amide O-atom of the peptide unit adjacent to the
five-membered ring of a neighboring peptide molecule and thereby links the
peptide molecules into extended chains which run parallel to the x-axis and have a
graph set motif of C(10). N(16)-H forms an intermolecular H-bond with the O-
atom of the H2O molecule. In turn, the H2O molecule donates H-bonds to amide
O-atoms in two different neighboring peptide molecules. One of these interactions
embeds the H2O molecule between two peptide molecules in the same chain
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created by the N(13)-H…O H-bond. The other interaction also involves these
chains, but with the sense of the interaction running along the chain in the
opposite direction. The chains incorporating H2O and peptide molecules
alternately, have binary graph set motifs of C22(13) and C
2
2(12). The cation forms
an intermolecular H-bond via N(37)-H with an amide O-atom of an adjacent
peptide molecule; graph set motif D. Finally, most amide NH groups in the
peptide molecule have a close intramolecular ‘sideways’ contact with an adjacent
amide N-atom. These interactions have very sharp N-H…O angles and therefore
may be simply a result of the geometrical arrangement within the molecule, rather
than being true H-bonds.
Table 3
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Legends
Fig.1 ORTEP Plot [21] of the molecular structure of 1. The co-crystallized Et(i-
Pr)2NH+PF6- and  H2O are not shown (50% probability ellipsoids, arbitrary
numbering of the atoms)
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Table 1. Torsion Angles [°] for Cyclo(Pro-Aib-Gly-Aib-Aib-Phe) (1)
Residue φ ψ ω
Pro1 -54.7(4) -35.4(5) +179.5(3)
Aib2 -65.1(5) -13.8(5) -165.9(4)
Gly3 +118.6(4) +169.5(3) +173.0(4)
Aib4 +53.9(5) +46.7(5) +173.1(3)
Aib5 +80.2(5) +10.1(5) +170.6(4)
Phe6 -122.0(4) +168.0(3) +176.9(3)
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Table 2. Hydrogen Bonding Geometry for Cyclo(Pro-Aib-Gly-Aib-Aib-Phe) 1.
Donor (D-H) Acceptor (A) D-H [Å] H...A [Å] D...A [Å] D-H...A [°]
N(1)-H(1) O(12) 0.88 2.25 3.063 (5) 153
N(1)-H(1) N(16) 0.88 2.23 2.684 (5) 112
N(7)-H(7) N(4) 0.88 2.43 2.793 (5) 105
N(7)-H(7) F(3a) 0.88 2.42 3.220 (5) 152
N(7)-H(7) F(2b) 0.88 2.43 2.904 (9) 114
N(7)-H(7) F(3c) 0.88 2.20 2.916 (8) 139
N(10)-H(10) O(3) 0.88 2.01 2.852 (4) 159
N(10)-H(10) N(7) 0.88 2.32 2.748 (5) 110
N(13)-H(13) O(6i) 0.88 2.08 2.924 (5) 159
N(16)-H(16) N(13) 0.88 2.53 2.868 (5) 104
N(16)-H(16) O(44) 0.88 2.18 3.032 (5) 162
N(37)-H(37) O(18ii) 0.93 1.92 2.829 (5) 165
O(44)-H(441) O(6i) 0.84 (1) 1.97 (1) 2.808 (6) 173 (10)
O(44)-H(442) O(9iii) 0.84 (1) 2.05 (4) 2.842 (5) 156 (9)
Superscripts in atom labels refer to the peptide molecule in the following symmetry-related positions:
i –1/2+x, -1/2+y, -z; ii –1/2+x, 1/2-y, -z; iii 1/2+x, -1/2-y, -z.
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Table 3. Crystallographic Data of 1•Et(i-Pr)2NH+PF6-•H2O.
Crystallized from AcOEt / EtOH / hexane
Empirical formula C36H62F6N7PO7
Formula weight [g mol-1] 849.89
Crystal color, habit colorless, plate
Crystal dimensions [mm] 0.05 × 0.15 × 0.30
Temperature [K] 160(1)
Crystal system orthorhombic
Space group P212121
Z 4
Reflections for cell determination 4318
2θ range for cell determination [°] 4-50
Unit cell parameters a [Å] 8.7953(1)
b [Å] 18.4796(2)
c [Å] 26.6501(4)
V [Å3] 4331.54(9)
Dx [g cm-3] 1.303
µ(MoKα) [mm-1] 0.142
Scan type φ and ω
2θ(max) [°] 50
Total reflections measured 45195
Symmetry independent reflections 4296
Reflections with I>2σ(I) 3478
Reflections used in refinement 4287
Parameters refined; restraints 668; 997
Final R(F) [I>2σ(I) reflections] 0.0549
wR(F2) (all data) 0.1547
Weights: w = [σ2(Fo2) + (0.0900P)2 + 2.2715P]-1; where P = (Fo2+2Fc2)/3
Goodness of fit 1.049
Secondary extinction coefficient 0.004(1)
Final Δmax/σ 0.012
Δρ (max; min) [e Å-3] 0.51; -0.27
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Fig. 1. ORTEP Plot [21] of the molecular structure of 1. The co-crystallized Et(i-
Pr)2NH+PF6- and H2O are not shown (50% probability ellipsoids, arbitrary
numbering of the atoms)
